

CURRICULUM VITAE (updated on December 10, 2025)

Wei Li, PhD

UTHSC Distinguished Professor

Director of UTHSC Drug Discovery Center

Department of Pharmaceutical Sciences, College of Pharmacy

University of Tennessee Health Science Center

881 Madison Avenue, Room 561, Memphis, TN 38163

Tel: (901)448-7532; Email: wli@uthsc.edu; Webpage: <https://li.lab.uthsc.edu/>

Founder and CSO

SEAK Therapeutics, LLC

3 N Dunlap Street, Suite C303, Memphis, TN 38163

Tel: (901)3409109; Email: wli.uthsc@gmail.com; Website: <http://seaktherapeutics.com>

EDUCATION HISTORY

B. S. 1992 (Chemistry) University of Science and Technology of China (USTC)

Ph.D. 1999 (Chemistry) Columbia University in the City of New York

PROFESSIONAL EXPERIENCE

1992 – 1994 Graduate student, Dalian Inst. of Chemical Physics, Chinese Academy of Sciences

1994 – 1999 Graduate Research Assistant, Columbia University in the City of New York

1999 – 2001 Instructor and Director of Instrument Facility, University of Tennessee HSC

2001 – 2004 Assistant Professor and Director of Instrument Facility, UTHSC

2004 – 2009 Assistant Professor (tenure-track) and Director of Instrument Facility, UTHSC

2009 – 2014 Associate Professor and Director of Instrument Facility, UTHSC

2014 – 2020 Professor, UTHSC

2017 – present Director, UTHSC College of Pharmacy Drug Discovery Center

2017 – 2019 Member, the West Cancer Center, Memphis, TN

2018 – present Founder and CSO, SEAK Therapeutics LLC

2020 – present UTHSC Distinguished Professor

2023 – present Executive Committee member, University of Tennessee Research Foundation

2024 – present Co-Leader, Chemical Biology Program, UTHSC Cancer Center

HONORS/AWARDS

Faculty Fellowship, Columbia University, 1994-1999

Zhang ZhongZhi Fellowship, University of Science and Technology of China, 1991

Innovation Award, University of Tennessee Research Foundation, 2010

Research Award, University of Tennessee Research Foundation, 2012

Research Award, University of Tennessee Research Foundation, 2014

Health Care Heroes Award in the category of Innovation, the Memphis Business Journal, 2022

Innovator of the Year Award, the University of Tennessee Research Foundation, 2024

SOCIETY MEMBERSHIPS

American Chemical Society (ACS)

American Association for Cancer Research (AACR)

American Association for Pharmaceutical Sciences (AAPS)

American Society for Pharmacology and Experimental Therapeutics (ASPET)

PROFESSIONAL ORGANIZATION APPOINTMENTS:

- Secretary, American Chemical Society Memphis Local Section, 2015-2017.
- Vice President and Executive Committee Member, MALTO (Medicinal Chemistry-Pharmacognosy Meeting-in-Miniature), 2016-present.
- Member, Award Committee, AAPS, 2020-present
- Member, Executive Committee of the ASPET Division for Drug Discovery and Development (DDD), 2022-present
- Secretary/Treasurer-elect (7/2024-6/2025); Secretary/Treasurer (7/2025-6/2026 term); Chair-Elect (7/2025-6/2026); and Chair (7/2026-6/2027 term), Division of Drug Discovery and Development, ASPET.

EDITORIAL APPOINTMENTS:

- Guest Editor, **Pharmaceutical Research**, Theme Issue on tubulin inhibitors, 2012.
- Guest editor, **Molecules**, Theme Issue on Tubulin Inhibitors, 2016
- Guest editor with Dr. Guan Chen at MCW, **Acta Pharmaceutica Sinica B**, Theme Issue on signal transduction and cancer drug discovery, 2017-2018.
- Guest Editor with Dr. Kevin Piney at Baylor, **Molecules**, Special Issue Tubulin 2021, 2020-2021.
- Guest Editor, **Molecules**, Special Issue to honor Dr. Duane D Miller, 2020-2021
- Guest Editor, **Frontiers in Pharmacology**, Special Issue on cancer drug resistance, 2023.
- Guest Editor, **Frontiers in Immunology**, Special Issue on small molecule immunotherapy potentiators. 2025-2026
- Editorial Board Member, and Section Editor (Anti-Cancer Agents), **Current Med Chem**, 2014-2020.
- Editorial Board Member, **Acta Pharmaceutica Sinica B**, 2016-present
- Editorial Board Member, **Molecules**, 2018-present.
- Editorial Board Member, **Genes & Diseases**, 2018-present
- Editorial Board Member, **Cancer Letters**, 2020-2024
- **Ad-hoc journal reviewer:**
 - ACS Applied BioMaterials
 - Acta Pharmaceutica Sinica B
 - Anti-cancer Agents in Med Chemistry
 - Bioorganic Chemistry
 - Bioorganic Medicinal Chemistry
 - Bioorganic Medicinal Chemistry Letters
 - BMC Cancer
 - British Journal of Cancer
 - British Journal of Pharmacology
 - Cancer Letters
 - Cancer Research
 - European Journal of Medicinal Chemistry
 - Expert Opinion on Drug Discovery
 - Expert Opinion on Biological Therapy
 - Genes & Diseases
 - International Journal of Nanomedicine
 - International J of Biological Sciences
 - J Pharmacol & Exp Therapeutics
 - Journal of American Chemical Society
 - J Experimental & Clinical Cancer Res
 - Journal of Medicinal Chemistry
 - Materials Science and Engineering C
 - Medicinal Research Review
 - Molecular Cancer
 - Molecular Cancer Therapeutics
 - Molecular Diversity
 - Molecules
 - Molecular Therapy
 - Nature
 - Nature Communications
 - Pharmacological Reviews
 - Pharmacology Research & Perspective
 - PLoS One
 - PNAS
 - Royal Society of Chemistry Journals
 - Scientific Reports
 - The Open Magnetic Resonance Journal

INVENTED INVESTIGATIONAL NEW DRUG (IND) ADVANCED TO CLINICAL TRIALS

- Sabizabulin (other names known as ABI-231, VERU-111, GTx-230), originally invented and synthesized in the Li lab as compound ABI-231. It went through several clinical trials in prostate cancer and hospitalized COVID-19 patients. Currently licensed and in commercial development by Veru, Inc.

GRANT REVIEWER

- National Institute of Health
 - 2011/03: ZRG1 BCMB-U 30
 - 2012/03: ZRG1 BCMB-R 30
 - 2012/07: ZRG1 BCMB-D 30
 - 2012/11: NCI CDDT SBIR/STTR
 - 2014/03: NCI CDDT SBIR/STTR
 - 2014/07: NCI CDDT SBIR/STTR
 - 2015/03: NCI CDDT SBIR/STTR
 - 2015/06: NCI CDDT SBIR/STTR
 - 2015/12: NCI CDDT SBIR/STTR
 - 2016/01: NCI ZRG1 OTC-Y (02) M
 - 2016/03: NCI CDDT SBIR/STTR
 - 2016/06: NCI CDDT SBIR/STTR
 - 2016/09: NCI ZRG1 OTC-K04
 - 2016/11: NCI CDDT SBIR/STTR
 - 2016/12: NCI CDDT SBIR/STTR
 - 2017/03: NCI CDDT SBIR/STTR
 - 2017/10: ZRG1 BCMB-D (30)
 - 2017/10: ZRG1 BCMB-N (07)
 - 2018/03: NCI CDDR SBIR/STTR
 - 2018/07: NIH ZRG1 IDM-C(50)R
 - 2018/11: NIH CDDT SBIR/STTR
 - 2019/10-12: NIH Director's New Innovator Award DP2 Award-2020, ZRG1-MOSS-R70
 - 2020/03: NCI OTC-T SBIR/STTR
 - 2020/10-12: NIH Director's New Innovator DP2 Award-2021
 - 2021/10: NIH EBIT

- 2021/10-12: NIH Director's New Innovator DP2 Award – 2022
- 2022/06: NCI CDDT SBIR/STTR
- 2025/03: NCI MCTA
- 2026/01: NCI MCTA
- National Science Foundation
- US Army
- Human Frontier Science Program
- American Chemical Society
- Florida Department of Health
- Estonian Science Foundation (ETF)
- Oklahoma Center for the Advancement of Science & Technology (OCAST) -2015, 2017, 2019-2021
- Czech Science Foundation --2017
- The Cancer Society of New Zealand – 2017
- Prostate Cancer UK – 2019
- Health Research Council of New Zealand – 2019
- ITMO Cancer of the French National Alliance for Life and Health Sciences (AVIESAN)-2019, 2020
- French National Cancer Institute (INCa) – 2019-2021
- University of Maryland Pilot Grant Program -- 2022
- UT San Antonio and Mays Cancer Center Pilot Grant Program –2/2023
- 2023/09: NCI SPORE (P50)
- 2024/07: NCI SBIR/STTR
- 2024/09: NCI ZRG1 CTH-C (55)

COURSES TAUGHT

Medicinal Chemistry I (MEDC112/612),	instructor (2006-present)
Medicinal Chemistry II (MEDC122/622),	instructor (2015-present)
Introduction to Pharmacy (PHSC115),	co-facilitator (2008)
Research Techniques in Medicinal Chemistry (MEDC813)	course director (2005-present)
Research Techniques in Medicinal Chemistry II (MEDC823)	course director (2005-present)
Medicinal Chemistry Journal Club (MEDC819)	instructor (2006-present)

CURRENT RESEARCH FUNDING

EXTERNAL ACTIVE GRANTS AND CONTRACTS:

- 1. 1R01CA295996-01A1 Li (contact PI); Wang (MPI) 8/2025-7/2030**
 “Targeted MDM2 degradation for improved treatment for triple-negative breast cancer”
 Total cost: \$3.24 million.
- 2. 1R01CA276152-01 (NIH/NCI) Li (contact PI); Seagroves (MPI) 4/2023-3/2028**
 “Targeting brain and bone metastases in metastatic breast cancer for improved patient survival”
 The goal of this project is to develop brain-penetrable novel tubulin inhibitors to treat breast cancer brain metastasis, and develop small molecule drug conjugates to treat breast cancer bone metastasis.
 Total cost \$3,074,470.
- 3. HT9425-23-1-0216 (DoD) Li (PI) 7/2023-6/2027**
 “Development of an Orally Available and Low-Toxic Chemotherapy for Improved Ovarian Cancer Therapy”
 The goal of this project is to evaluate a new therapeutic agent for drug-resistant ovarian cancer.
 Total direct cost: \$600,000. Total cost: \$924,000.
- 4. 1R01AG072703 (NIH/NIA) Liao (contact PI); Li and Bhaskar (MPIs) 6/2022-5/2027**
 “Validation of a novel tau clearance mechanism”
 Total cost: \$3,595,305.
- 5. 1R01CA148706 (NIH/NCI) Li (contact PI); Miller (MPI) 8/2021-7/2026**
 “Targeting the colchicine binding site in tubulin for cancer therapy”
 This is the 3rd cycle of this project and it aims to continue our efforts in developing orally available tubulin inhibitors that interact with the colchicine-binding site in tubulin for cancer therapy.
 Five-year total direct: \$1,328,535, total cost \$1,962,575.
- 6. 1R01CA240447-01A1 (NIH/NCI) Li (contact PI); Zhou (MPI) 7/2020-6/2026 (NCE 7/2025-6/2026)**
 “Dual inhibition of MDM2 and XIAP as a therapeutic strategy in cancer”
 The goal of this project is to develop a potential new agent for pediatric cancers.

Total cost: \$2.72 million.

7. Co-I: R01CA276135-01A1 (NIH/NCI) Zhou (PI) 12/2023-11/2028

“Discovery of a novel MDM2-tubulin signaling pathway as a therapeutic target in AML”

Total cost: about \$2.7 million.

8. Co-I: R01NS128336 (NIH/NIDDS) Mahato (PI) 7/2022-5/2027

“Lipid nanomedicine targeting multiple signaling pathways of medulloblastoma”

The goal of this project is to develop new RVG peptide decorated lipid nanoparticles for co-delivery of potent BRD4/PI3K and MDM2/XIAP dual inhibitors.

Total cost: \$2,391,270.

9. R16GM154786-01 (NIH/NIGMS) Role: Mentor and Co-I (PI: Banerjee) 7/2024-6/2028

“Discovery of fused heterocyclic pyrazine based novel anti-mitotic agents for metastatic melanoma”

Total cost: \$684,757. Li lab share: \$138,600.

10. PI: R41CA310186-01 9/2025-8/2026

“Development of a potent and highly brain-penetrable antimitotic agent SEAK193 to treat breast cancer brain metastasis”

Total cost: \$399,981 (awardee: SEAK Therapeutics, LLC)

PENDING EXTERNAL GRANTS: None.

RELINQUISHED EXTERNAL GRANT

**1R01CA239160-01A1 Wei Li (contact PI); Seagroves, Miller (MPIs) 6/2020-5/2025
NIH/NCI**

Impact score 20; Percentile 2%.

Funded but relinquished on 2/11/2020 due to the partial overlap with a DoD grant Breast Cancer Research Program, Breakthrough Level II with partner-PI option: BC190092.

UTHSC INTERNAL RESEARCH SUPPORT

1. Distinguished Professor Research Support for Li 9/2020-present
UTHSC Chancellor’s office and UTHSC College of Pharmacy.

2. UTCOP Drug Discovery Center 7/2017-present
UTHSC College of Pharmacy

COMPLETED SUPPORT

55. 1R61/R33 NS124923 (NIH/NINDS) Jiang (contact PI); Li (MPI) 12/2021-11/2025

“Targeting TRPC3 Channels for Epileptic Seizures”

The goal of this project is to develop a selective TRPC3 inhibitor as a potential targeted therapy for epilepsy.

Total direct cost: \$750,000; total cost at 54% IDC: \$1.155 million

54. Co-I: 1R24EY029950 (NIH/NEI) Jablonski (PI) 3/2020-2/2025

“Novel Extended Release Glaucoma Therapy for Once Daily Dosing”

The goal of this project is to develop a new agent and its formulations for glaucoma treatment.

Five year total budget: \$4.94 millions.

53. R41NS135658-01 (NIH/NINDS) Li (PI) 9/2023-11/2024

“Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment”

Awarded to SEAK Therapeutics LLC (Li’s startup company)

Total cost: \$429,932

52. 1S10OD034237-01 (NIH) Role: Minor User (PI: Paige Vinson) 8/2023-8/2024

“An Automated Compound Management System for Small Molecule Drug Discovery”

Direct cost: \$1,038,536, equipment grant, no indirect cost allowed by NIH

51. Co-I: UTRF Maturation Grant Quarles (PI) 1/2023-10/2023

“Optimizing small molecule mechanomimetics to treat age-related osteoporosis”

Total cost: \$30,000

50. BC190092 (DoD) Li (PI); Seagroves (Partner PI) 3/2020-2/2024

DoD Breast Cancer Research Program, Breakthrough Level II Award with Partnership Option

Total budget: \$2,269,056 for the duration of 3 years

W81XWH2010011: Li's part of the project \$1,271,866

W81XWH2010019: Seagroves' part of the project \$997,190

“Discovery of orally bioavailable tubulin inhibitors to overcome taxane resistance in metastatic breast cancer”

The goal of this project to develop a more efficacious therapeutic agent for triple negative breast cancers.

49. New Grant Support -August 2021 Wei Li (PI) 8/2021-7/2023

UTHSC Vice Chancellor for Research Office

This new grant support is to support the generation of additional preliminary data for the resubmission of an R01 grant application that scored 38.

48. UTHSC Functional Genomics CORNET grant PIs (Yue, Li, Zhang) 7/2022-6/2023

“An ovarian cancer mouse model recapitulating human disease phenotype”

47. New Grant Support – October 2022 Li (PI); Miller, Seagroves (MPIs) 10/2022-9/2024

UTHSC Vice Chancellor for Research Office

This new grant support is to support the generation of additional key preliminary data for resubmission of an NCI R01 grant application.

46. Sponsored Research Agreement #1 Wei Li (PI) 7/2019-6/2023

Private Industry, total amount: \$100,000.

45. Sponsored Research Agreement #2 Wei Li and Duane Miller (MPIs) 1/2020-6/2023

44. Oxnard Foundation Wei Li (PI) 7/2019-2/2023

This foundation grant is to support research in the Li lab to develop a new small molecule compound as potentially more effective treatments for pancreatic cancer.

Total direct amount: \$120,000 (\$40,000/year direct).

43. 1R43CA257324-01 (NIH/NCI) Wei Li and Zhongzhi Wu (MPIs) 9/2020-12/2022

“Feasibility study of developing SEAK-114 for the treatment of pediatric cancers”

The goal of this project is to determine the feasibility of SEAK-114 as a potential drug for cancer.

One-year total amount: \$399,964

Role: MPI for the grant; Founder and owner of the awardee company, SEAK Therapeutics LLC.

42. 1R01CA193609-01A1 (NCI) Wei Li (PI) 5/2016-4/2022

“Selective targeting survivin for cancer therapy”

The goal of this project is to use integrated medicinal chemistry, structure biology, and molecule biology methods to develop potent and selective inhibitors for survivin as a potential therapeutic agent for cancer therapy.

Five year total direct \$1,331,505, total cost: \$1,913,635.

41. 1R43 CA246788-01 (NIH/NCI) Zhongzhi Wu (PI) 9/2019-12/2020

Role: subcontract PI (transfer to Dr. Miller in consideration of my COI as advised by UTHSC)

“Development of a dual MDM2/XIAP inhibitor with a high therapeutic index for pediatric cancers”

This is a one-year, Phase I SBIR grant application that I wrote and submitted in April of 2019 for my company, SEAK Therapeutics LLC. Jim Wu is a research assistant professor in my lab. Amount: \$299,830

Role: Founder and owner of the awardee company: SEAK Therapeutics LLC.

40. 3R43 CA246788-01S1 (NIH/NCI) Zhongzhi Wu (PI) 8/2020-12/2020

Supplement award to R43CA246788 for participation of the NIH I-Corps training for the Sept-Nov 2020 cohort.

Amount: \$55,000.

Role: Founder and owner of the awardee company: SEAK Therapeutics LLC.

39. 4R33AR07158-03 (NIH/NIAMS) Darryl Quarles (PI) 8/2020-7/2021

“Polycystins/TAZ as a novel therapeutic target to treat osteoporosis”

This goal of this R33 grant is to continue the work after the successful completion of the R61 phase which ends in 9/2020. The major goal of this R61/R33 project is to validate the Pkd1/Pkd2/TAZ complex as a therapeutic target in bone, and to develop a new class of bone anabolic agents that activate this complex to increased bone mass through unique actions to stimulate Ob-mediated bone formation and inhibit bone marrow adipogenesis. Amount: \$380,000.

Role: Co-I

38. 2020 UTHSC CORNET AWARD Seagroves, Li, and Miller (MPIs) 9/2020-8/2021

UTHSC Vice Chancellor for Research Office

“Testing efficacy of an orally bioavailable tubulin inhibitor (VERU-111) to inhibit taxane-sensitive and taxane-resistant HER2+ breast cancers”

Total direct amount: \$50,000.

37. New Grant Support #3 Wei Li 10/2018-9/2020

UTHSC Vice Chancellor for Research Office

This new grant support is to support the generation of additional preliminary data for resubmission of an NIH R01 that received a score of 13.0 percentile (impact score 29).

Total direct amount: \$30,000.

36. 1R61AR073518 (NIH/NIAMS) Darryl Quarles (PI) 4/2018-9/2020

“Polycystins/TAZ as a novel therapeutic target to treat osteoporosis”

This goal of this R61 grant is to validate the Pkd1/Pkd2/TAZ complex as a therapeutic target in bone, and to develop a new class of bone anabolic agents that activate this complex to increased bone mass through unique actions to stimulate Ob-mediated bone formation and inhibit bone marrow adipogenesis. Upon satisfactory completion of this R61 Phase, an R33 phase will likely be awarded. Amount: \$760,000.

Role: Co-I

35. New Grant Support #2 Wei Li and Tiffany Seagroves (MPIs) 10/2018-2/2020

UTHSC Vice Chancellor for Research Office

This new grant support is to support the generation of additional preliminary data for resubmission of a DoD grant application that scored 1.9.

Total direct amount: \$30,000.

34. New Grant Support #1 Wei Li and Glen Palmer (PIs) 7/2017-6/2019

UTHSC Vice Chancellor for Research Office

This new grant support is to support the generation of additional preliminary data for resubmission of an R21 that scored 10.0 percentile (impact score 26).

Total direct amount: \$20,000.

33. West Cancer Center Research Grant Wei Li (PI) 1/2018-12/2019

The West Cancer Center

“Orally Bioavailable Tubulin Inhibitors Overcoming Taxane Resistance for Breast Cancer”

This grant is to facilitate the development of new generation of tubulin inhibitors that can overcome taxane resistant for improved treatment of metastatic breast cancer, especially triple negative breast cancer.

Total direct cost: \$50,000, no indirect cost allowed.

32. Co-I, Glaucoma Research Foundation Grant Monica Jablonski (PI) 2/2018-1/2019

Glaucoma Research Foundation

“Extended release IOP-lowering formulation”

This project aims to develop novel formulations of IOP lowering agents for glaucoma treatment.

Role: Co-I

Total direct amount to the Li lab: \$4,000; no indirect cost allowed.

31. PI: UTCOP Seed Research Grant Wei Li (PI) 10/2017-6/2018

University of Tennessee College of Pharmacy internal grant

This seed research grant aims to support generating additional preliminary data for the resubmission of a previously

scored (8.0 percentile, 2016) but not funded NCI R21 grant application.
Total direct cost support: \$15,000.

30. PI: UTHSC Collaborative Research Network (CORNET) Grant, MPI: Kczorowski and Li

University of Tennessee Health Science Center

“Selective targeting of TRPC3 ion channel for Alzheimer’s disease therapy”

5/1/2016-4/30/2017, \$50,000 total direct

29. Co-I: UTHSC Collaborative Research Network (CORNET) Grant, PI: Liang Hong

University of Tennessee Health Science Center

“Novel 20-hydroxyvitamin D3 (20D3) analogues for periodontitis treatment”

5/1/2016-4/30/2017, \$50,000 total direct (Li lab share: \$20,000)

28. PI: 1R01CA148706-06 (NIH/NCI, MPI: Duane D Miller)

1/2016-7/2021

Title: “Discovery of novel thiazole compounds for treating advanced melanoma”

This is the 2nd cycle of this project and the goal of this project is to develop new generations of orally available tubulin inhibitors targeting the colchicine binding site for advance melanoma and potentially other cancers.

Five year total direct: \$1.3 million, total cost: \$1.8 million.

27. PI: Grant Incentive Grants

University of Tennessee Health Science Center

\$25,000, 7/2015-12/2016, support for resubmission of an R21 application (17% for A0). The resubmission obtained a score of 8.0% (impact score=23), missed the NCI payline at 7.0% for FY2016.

26. PI: UTHSC Strategic Investment Funds (SIF)

11/2011-10/2016

University of Tennessee Health Science Center

Institutional commitment to two NIH instrument grants to provide 5 years support for a full-time staff scientist and maintenance expenses to maintain the department shared instrument facility including two S10 awarded instruments (a 400 MHz NMR and a high resolution UPLC/q-TOF mass spectrometer, PIs: Wei Li). Total: \$560,000.

25. PI: 1R21AR063242-01A1, MPI: Wei Li (NIH contact); Duane D. Miller

4/2013-3/2016

NIH/NIAMS

Title: “Discovery of tissue-selective, nonhypercalcemic VDR modulators for RA treatment”

Total direct cost: \$233,750, total cost: \$350,625

24. PI: 1R01CA148706-01A1 (NIH/NCI)

PI: Wei Li

1/2011-12/2015

Title: “Discovery of novel thiazole compounds for treating advanced melanoma”

The goal of this project is to develop new generations of orally available tubulin inhibitors targeting the colchicine binding site for advance melanoma and potentially other cancers.

Five year total direct: \$1,018,825, total cost: \$1,507,861.

23. PI: Grant Incentive Grants

1/2015-12/2015

University of Tennessee Health Science Center

\$25,000, support for resubmission of an R01 application (16% for A0). Resubmission of this R01 scored at 5% and funded for 2016-2021.

22. PI: Technology Maturation Award

1/2015-10/2015

University of Tennessee Research Foundation

Title: “Stability and in vivo pharmacokinetic evaluation of selective survivin inhibitors in rats”

Total direct: \$15,000; total amount: \$15,000.

21. PI: 2015 UTHSC College of Pharmacy Seed Research Grant

11/2014-6/2015

UTHSC College of Pharmacy (Internal funding)

Title: “Discovery of selective survivin inhibitors”

Amount: \$15,000

20. PI: 2015 UTHSC College of Pharmacy Equipment Grant

1/2015 – 6/2015

UTHSC College of Pharmacy (Internal funding)

Title: “Purchase of a Western Blot imaging system for research”

Amount: \$16,995

19. Co-I: 1R01AR056666-01A2 (NIAMS; PI: Andrzej T. Slominski)

8/2011-7/2016

Title: “Role of exogenous melatonin in skin biology”

Five year total: \$1,662,408.

Role: Co-investigator

18. Co-I: 1S10OD016226-01A1 (PI: Bernd Meibohm) 4/2014-4/2015

Title: "MASS SPECTROMETER FOR SMALL MOLECULE DRUG DEVELOPMENT"

Direct cost: \$315,651, instrument, no indirect cost.

This shared instrumentation application is for an AB Sciex Triple Quad 4500 triple quadrupole mass spectrometer as replacement for an outdated shared liquid chromatography-mass spectrometry instrument.

Role: Co-I (Major user)

17. Co-I: 2014 West Cancer Center Research Support Award 1/2014-12/2014

PI: Slominski

Title: "Pre-clinical testing of anti-melanoma activity of 20-hydroxyvitamin D3"

Direct cost: \$50,000, no indirect cost.

The goal of is to test in vivo anti-melanoma activity of novel non-calcemic analogs of vitamin D.

16. Co-I: 2R01AR052190-06A1 (NIAMS, PI: Andrzej Slominski) 10/2013-9/2014

Title: "Novel Biosynthetic Pathway for Secosteroids and the Skin"

Direct cost: \$200,000, total cost: \$300,000 for the year.

Role: Co-investigator

15. PI: UTHSC Contract# 8500035962 10/2013-12/2013

Source: Private Company

Title: "UPLC/UV analysis of active components in sunscreen samples"

Service Contract: \$4,415 to UTHSC

14. PI: 1S10OD010678-01 (NIH) 5/2012-4/2013

Title: "Acquisition of a Q-TOF Mass Spectrometer"

Direct cost: \$325,000, equipment grant, no indirect cost allowed by NIH

13. PI: 2012 Dean's Research Enhancement Program 11/2012-6/2013

UTHSC College of Pharmacy (Internal funding)

Title: "Mechanistic and in vivo efficacy studies against breast tumors using a novel HIF-1alpha inhibitor"

Amount: 15,000

12. Co-I: 2012 Dean's Research Enhancement Program (PI: Bob Moore) 11/2012-6/2013

UTHSC College of Pharmacy (Internal funding)

Title: "Acquisition of a Meso Scale Discovery SECTOR Imager 2400"

Amount: \$35,000

11. Co-I: 1R01 AR052190-01A2 (NIAMS, PI: Andrzej T. Slominski) 8/2006-7/2012

Title: "Novel Biosynthetic Pathway for Secosteroids and the Skin"

Five year total award amount: \$1,922,190

10. PI: Dean's Enhancement Program for Research Equipment 5/2012-6/2012

College of Pharmacy, University of Tennessee Health Science Center (UTHSC internal fund)

Title: "Purchase of an inverted fluorescence microscope"

Total cost: \$15,000

9. PI: Pilot Study to Assess Blood Chemistry at High Dose 20S-D3 in Mice 3/2012-6/2012

University of Tennessee Research Foundation

Total cost: \$3,000.

8. PI: Technology Maturation Award 1/2011-10/2011

University of Tennessee Research Foundation

Title: "Preclinical studies of new vitamin D analogs as potential agents for arthritis"

Total direct: \$15,000; total amount: \$15,000.

7. PI: RR-026377-01 (NIH/NCRR) 8/2010-8/2011

Title: "Acquisition of a 400M NMR with an autosampler"

Total direct: \$252,900, total amount: \$252,900, equipment grant, no indirect cost allowed by NIH.

6. PI: 1R15CA125623-01A2 (NIH/NCI) 3/2008-2/2011

National Cancer Institute, NIH

Title: "Discovery of Novel Cytotoxic Agents for Advanced Melanoma"

Total direct: \$150,000, total amount: \$219,000

5. PI: Technology Maturation Award

2/2009-10/2009

University of Tennessee Research Foundation, University of Tennessee

Title "In vivo Assessment of Efficacy of Novel Thiazole Compounds"

Total direct: \$15,000; Total amount: \$15,000.

4. PI: UTHSC College of Pharmacy Seed Research Fund

7/2006-6/2007

Title: "Development of Novel Cytotoxic Agents towards Advanced Melanoma"

Total direct: \$9,300; total amount: \$9,300

3. Co-I: 1R03AI054798-01 (NIAID, PI: Richard Lee)

5/2003-12/2006

Title: "Whole Cell NMR Studies of Mycobacteria"

Total direct: \$100,000; Total amount: \$146,000

2. Co-I: DAMD17-01-0830 (PI: Duane Miller)

9/2001-10/2005

Department of Defense

Title: "Selective Cytotoxic Phospholipids for Prostate Cancer"

Total cost: \$556,364

1. College of Pharmacy, faculty start-up fund for Dr. Wei Li

7/2004-6/2007

\$40,000/year (\$120,000 total).

EXTERNAL PROMOTION/TENURE REFEREE

- 2014** Texas Tech University College of Pharmacy (two faculty promotion/tenure)
- 2015** University of Texas MD Anderson Cancer Center (faculty promotion)
- 2016** University of Houston College of Pharmacy (faculty promotion)
- 2016** Texas Tech University College of Pharmacy (faculty promotion)
- 2016** University of Arkansas College of Pharmacy (faculty promotion)
- 2017** King Saud Bin Abdulaziz University for Health Sciences, Saudi Arabia (faculty promotion)
- 2017** Ohio State University College of Pharmacy (faculty promotion)
- 2018** King Saud Bin Abdulaziz University for Health Sciences, Saudi Arabia (faculty promotion)
- 2018** University of Hawaii College of Pharmacy (faculty promotion)
- 2019** Jordan University of Science and Technology (faculty promotion)
- 2019** University of Minnesota (faculty tenure/promotion)
- 2020** University of Florida (faculty tenure)
- 2020** University of Tennessee College of Medicine (two faculty promotions)
- 2021** University of Nebraska Medical Center (faculty tenure/promotion)
- 2021** University of Memphis (faculty promotion)
- 2022** Lerner Research Institute, Cleveland Clinic (faculty promotion)
- 2022** University of Houston (faculty tenure/promotion)
- 2022** University of Tennessee College of Medicine (faculty promotion)
- 2023** University of Tennessee College of Medicine (faculty promotion and tenure)
- 2023** Case Western Reserve University School of Medicine (faculty promotion).
- 2024** University of Maryland College of Pharmacy (faculty promotion)
- 2025** University of Miami School of Medicine (faculty promotion)
- 2025** UT Health Rio Grande Valley School of Medicine (faculty promotion).

INVITED LECTURES/PRESENTATIONS

1. "Implementation and Optimization of In-Cell Multi-dimensional HRMAS NMR". Invited talk, 57th Southeast/61st Southwest Joint Regional Meeting of the American Chemical Society, Memphis, TN, United States, November 1-4 (2005)
2. "Application of multi-dimensional HRMAS NMR in intact cells", Workshop on Metabonomics: a new tool for exploring biocomplexity, session chairman, Valencia, Spain, October 21st-24th, 2008.

3. "Noncalcemic vitamin D metabolites: from structure elucidation to in vivo efficacy studies", College of Pharmacy, the University of Mississippi, Feb 14, 2012.
4. "Discovery of tubulin inhibitors targeting the colchicine site for metastatic melanoma", College of Pharmacy, Western University of Health Sciences, September 16, 2014.
5. "Targeting the colchicine binding site in tubulin for advanced melanoma", University of South Alabama Mitchell Cancer Institute, January 20, 2015.
6. "Discovery of novel survivin inhibitors", session chair, 11th Chinese American Chemistry Professor Association annual meeting, Suzhou University, Jiangsu, China, June 21-24, 2015.
7. "Targeting the colchicine binding site in tubulin for advanced melanoma", Outstanding Alumni Lecture, Dalian Institute of Chemical Physics, the Chinese Academy of Sciences, Dalian, China, June 28, 2015.
8. "Discovery of novel tubulin inhibitors targeting the colchicine binding site", The University of Maryland at Baltimore Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, April, 2016.
9. "Discovery of novel tubulin and survivin inhibitor for cancer therapy", session chair, 12th Chinese American Chemistry Professor Association annual meeting, Sun Yat-Sen University, Guangzhou, China, June 23-25, 2016.
10. "Targeting tubulin polymerization for cancer therapy", Sichuan University, Chengdu, China, June 28, 2016.
11. "Targeting tubulin polymerization and survivin inhibitors for cancer therapy", Hormel Institute, University of Minnesota, August 26, 2016.
12. "Discovery of small molecule tubulin and selective survivin inhibitors", University of Houston College of Pharmacy, Houston, TX, September 19, 2016.
13. "Discovery and development of small molecule tubulin inhibitors for cancer therapy", Huazhong University of Science and Technology, Wuhan, China, January 6, 2017.
14. "Discovery of next generation anti-tubulin agents for cancer treatment", Medical College of Wisconsin Cancer Center Grant Round, Milwaukee, WI, September 7-8, 2017.
15. "Shared Analytical Chemistry Core Facility for Drug Discovery and Development at the College of Pharmacy", Hot Topics in Research, UTHSC Office of Research, September 26, 2017.
16. "Discovery of next generation anti-tubulin agents", one of the several Plenary Speakers in *Cancer Pharmacology Research Conference*, St. John's University, New York City, December 13-16, 2017.
17. "Discovery of a new generation of tubulin inhibitors overcoming taxane resistance", 15th Congress of Chemotherapeutic Pharmacology Specialized Committee of Chinese Pharmacological Society (CPS-CPSC), Chongqing, China, June 22-25, 2018.
18. "A new generation of orally available tubulin inhibitors: the discovery and development", Keynote speaker and session chair, Advanced Chemistry 2018, Paris, France, July 12-13, 2018.
19. Cancer Biology Meeting, St. Jude Children's Research Hospital, Memphis, TN, co-presentation with Dr. Stephen White, September 7, 2018.
20. Department of Chemistry & Biochemistry, and Harper Cancer Research Institute, University of Notre Dame, South Bend, IN, September 24, 2018.
21. Department of Pharmacology seminar program, College of Medicine, UTHSC, Memphis, TN, November 14, 2018.
22. Department of Chemistry, Hunter College, New York, NY, Feb 8, 2019.
23. Department of Medicinal Chemistry, University of Florida College of Pharmacy, Gainesville, FL, September 25, 2019.
24. Department of Medicinal Chemistry, Rutgers University, New Brunswick, NJ, Jan 15, 2020.
25. Department of Medicinal Chemistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, May 7, 2020.
26. ACACR Summer Session Zoom Conference, "New wine in an old bottle: the discovery and development of an oral tubulin inhibitor for cancer therapy", August 28, 2020.

27. UTHSC Cancer Center Grand Rounds, “New wines in old bottles: the development of an anti-mitotic agent Sabizabulin (VERU-111) for cancer and the discovery of a selective TRPC3 inhibitor for neurological diseases”, October 5, 2021.
28. Department of Pharmaceutical Sciences, University of Nebraska Medical Center, “New wines in old bottles: the development of Sabizabulin (VERU-111) for cancer and the discovery of a selective TRPC3 inhibitor for neurological diseases”, Omaha, NE, October 29, 2021.
29. UTHSC Cancer Center retreat, one of the two speakers representing the Chemical Biology Program, “Chemical Biology in Cancer Research: Examples of chemistry-biology collaborations”, December 4, 2021.
30. Health Sciences Entrepreneurship (HSE) Grand Rounds series, “The One-Mark Mile in a Marathon: First Tastes of Starting a Company in Developing a Small Molecule Drug”, Jan 20, 2022.
31. Department of Chemistry, University of Memphis, “The development of Sabizabulin for cancer and the discovery of a selective TRPC3 inhibitor for epilepsy”, Feb 11, 2022.
32. Glenn Family Breast Center at Winship Cancer Institute, Emory University School of Medicine, “The discovery of sabizabulin as a potential oral anti-mitotic agent for cancer and COVID-19 treatments”, August 3, 2022.
33. Department of Cancer Biology, Cleveland Clinic Lerner Research Institute, “Two examples of small molecule drug discovery projects: an oral tubulin inhibitor sabizabulin for cancer and a selective TRPC3 modulator for epilepsy indication”, September 2, 2022.
34. College of Pharmacy, University of Arkansas Medical Center, “The discovery and development of sabizabulin for metastatic cancer and the discovery of JW-65 for epilepsy indication”, December 4, 2022.
35. Department of Chemistry, Middle Tennessee State University, “Discovery of a New Generation of Tubulin Inhibitors that Overcame Taxane Resistance”, February 17, 2023.
36. Distinguished Lecturer in the Medicinal Chemistry Seminar Series, Department of Medicinal Chemistry, the University of Minnesota, “The discoveries of new anti-tubulin agents for cancer and selective TRPC3 modulators for CNS diseases”, September 26, 2023.
37. Invited speaker, for the session “Sub-stoichiometric Modulation of Proteins & Target Vulnerability”, in 2024 ACS Spring national meeting, New Orleans, LA, March 17-21, 2024.
38. “Discovery of selective TRPC3 inhibitors as a potential therapy for CNS disease indications”, UTHSC College of Medicine, Department of Physiology, Seminar series, Oct 3, 2024.
39. “Discovery of small molecules targeting tubulin for cancer and TRPC3 for epilepsy”, invited speaker, China Pharmaceutical University, Nanjing, China, November 11, 2024.
40. “The discovery and development of next-generation anti-mitotic agents for multidrug-resistant cancer”, the 2025 Tu Youyou Award Ceremony and Scholar Salon, as a member of the 2025 Tu Youyou Award Committee, Chicago, IL, Oct 3, 2025.
41. “A next generation of anti-mitotic agents for drug-resistant cancer: the discovery and development”, invited seminar speaker, UTHealth, Houston, Department of Chemistry and Molecular Biology seminar programs, TX, October 6, 2025.
42. Invited speaker and panelist, “Cancer Below the Surface: How the Body Speaks through the Mouth”, the University of Tennessee College of Dentistry, Office of Continuing Dental Education and 21st Century Initiative Oral Systemic and Population Based for All. Memphis, TN, October 8, 2025.
43. “The discoveries of brain penetrable tubulin inhibitors for breast cancer brain metastasis and selective TRPC3 inhibitors for epilepsy”, invited speaker, Center for Diagnostics and Therapeutics (CDT), Georgia State University, Atlanta, GA, December 2-4, 2025.
44. “Anti-mitotic agent SB-216 overcomes taxane resistance and shows efficacy against breast cancer brain metastasis”, invited speaker, Recent Advances In Chemical Biology – In Memory Of Koji Nakanishi, The Pioneer In Natural Product Chemistry On The Occasion Of His 100 Year Birthday, the 2025 PacifiChem, The International Chemical Congress of Pacific Basin Societies, Honolulu, HI, December 15, 2025 (scheduled).
45. Invited seminar speaker, Department of Pharmacology and Chemical Biology, Emory School of Medicine, Atlanta, GA, Feb 9-10, 2026 (scheduled)
46. Invited seminar speaker, School of Pharmacy, University of Mississippi, March 3, 2026. (scheduled)

CONSULTANT:

- Ad hoc consultant, MEDACorp, Leerink Swann LLC, 2006-2014
- Consultant, GTx Inc., 05/2012-10/2013
- Ad hoc consultant, RxBio, Inc., 5/2013-4/2014
- Ad hoc consultant, Oblon, Spivak, McClelland, Maier & Neustadt, L.L.P., 10/2013-12/2013
- Consultant, Kenion Pharmaceuticals, 2014-2017
- Consultant, Veru Inc., 2019-present
- Ad hoc Consultant, Guidepoint, 2023-present

ACADEMIC COMMITTEES AND OFFICES HELD

1. Member - Computing and Telecommunication Committee, 2003 – 2006
2. Member - Webpage Committee, College of Pharmacy, 2001-2003
3. Member - Physical Facility Committee, College of Pharmacy, 2001-2002
4. Member - New Pharmacy Building Planning Committee, College of Pharmacy, 2004-2005
5. Member - Faculty Enrichment Committee, College of Pharmacy, 2005-2015
6. Member – Faculty Search Committee for Medicinal Chemistry, 2009-2010, 2013, 2014
7. Member (Chair, 2011-2012)- Web and Technology Committee, College of Pharmacy, 2005-2012.
8. Chair - NMR Advisory Committee, Department of Pharmaceutical Sciences, 2010-present
9. Chair – Facility and Space subcommittee, Department of Pharmaceutical Science self-study, 2012.
10. Member - Exam Integration and Writing Committee, 2012-2015
11. Chair – HRMS Advisory Committee, Department of Pharmaceutical Sciences, 2012-present.
12. Member – New faculty search committee, 2013, 2014
13. Member -- Facilities & Resources Coordinating Committee, 2013—2015
14. Member – Promotion and Tenure Committee, College of Pharmacy, 2011-2014, 2016-present
15. Member – Graduate Education Committee, College of Pharmacy, 2014
16. Member – Faculty Search Committee, Department of Pharmaceutical Sciences, 2014-2015.
17. Member – Search committee for Chair of Pharmaceutical Sciences, College of Pharmacy, 2015-2017.
18. Member – Various subcommittee for developing new integrated curriculum, 2015-2016
19. Chair – Graduate Education Committee, College of Pharmacy, 2015-present
20. Chair – Faculty Search Committee for an Assistant Professor in Medicinal Chemistry, Department of Pharmaceutical Sciences, 2016-2017. Led to the successful hire of R21-funded faculty at the Assistant Professor level.
21. Chair – Faculty Search Committee for an Associate/Full Professor, Department of Pharmaceutical Sciences, 2017-2018. Led to the successful recruitment of an R01-funded faculty at the Associate Professor level.
22. Chair- Graduate Education Committee, College of Pharmacy, 2017-2020
23. Member - Graduate Education Committee, College of Pharmacy, 2020-present
24. Member – Internal Advisory Board for Medicinal Chemistry Core, UTHSC, 2017-present
25. Chair -- Faculty Search Committee for an R01-funded Associate/Full Professor, Department of Pharmaceutical Sciences, 2018-2019. Led to the successful recruitment of an R01-funded faculty at the rank of Associate Professor.
26. Member – UTHSC Vice Chancellor for Research Cabinet, 2018-2020; 2021-2022
27. Member --UTHSC Operational Strategic Plan for Research Committee, 2020 (for FY2022-FY2027)
28. Chair – UTHSC Medicinal Chemistry Core Internal Advisory Board, 2021-2025.
29. Member --- UTHSC Campus Core Facility Internal Advisory Board member, 2025-present

MENTORING JUNIOR FACULTY

1. Murali M. Yallapu, Ph.D., Assistant Professor, 2018-2019, UTHSC
2. Bhupesh Singla, Ph.D., Assistant Professor, 2022-present, UHTSC
3. Souvik Banerjee, Ph.D., Assistant Professor, 2024-present, Middle Tennessee State University (MTSU)
4. Roy Sudeshna, Ph.D., Associate Professor, 2024-present, UTHSC College of Pharmacy

FUNDRAISING ACTIVITY

As the Director of the UTCop Drug Discovery Center and with support from the administrations, raised over \$30,000 to establish a permanent endowment to establish the annual “Duane D. Miller Lectureship” in Drug Discovery and Development in 2023, and the “Duane D. Miller Graduate Student Award in Drug Discovery” to honor Dr. Duane D.

Miller who established the medicinal chemistry program at UTHSC College of Pharmacy. More information can be found at <https://www.uthsc.edu/pharmacy/research/duane-miller-endowment.php>

FELLOWS/STUDENTS TRAINED

Research Associate and Postdoctoral Researcher

Previous years:

1. Dr. Jianjun Chen, senior research associate, 2010-2014 (last known: Full Professor at South Medical University, China).
2. Dr. Dajun Chen, postdoctoral researcher, 1/2013-3/2013 (last known: a CRO company in Shanghai, China).
3. Dr. Srinivasa Marepally, postdoctoral researcher, 5/2013-2/2015 (last known: a CRO company in Houston, TX).
4. Dr. Yi Xue, Research Associate, 4/2015-3/2017 (last known: Research Associate at UTHSC).
5. Dr. Hongmei Cui, postdoctoral researcher, 2/2018 to 3/2019 (last known: Full Professor at Lanzhou University, China)
6. Dr. Foyez Mahmud, postdoctoral researcher, 3/2018-10/2019 (last known: postdoc at Rice University).
7. Dr. Sicheng Zhang, postdoctoral researcher, 4/2018-8/2021 (last known: Pharmaceutical company in China)
8. Dr. Deendyal Bhurta, postdoctoral researcher, 1/2024-5/2024 (last known: India)

Current postdocs and research associates in the group:

1. Dr. Zhongzhi (Jim) Wu, postdoctoral researcher, 9/2015-10/2017. Assistant Professor, 10/2017-6/2023; Associate Professor, 7/2023-present
2. Dr. Hao Chen, postdoctoral researcher, 10/2016-2020; Research Associate, 2020-2022; Assistant Professor, 2022-present.
3. Dr. Vijay Bonda, postdoctoral researcher, 1/2021-4/2024; Research Associate, 4/2024-present.
4. Dr. Yang Xie, postdoctoral researcher, 1/2022 – 4/2024; Research Associate, 4/2024-present.
5. Dr. Zisong Qi, postdoctoral researcher, 1/2024-present.

Graduate Student:

Previous years' graduate students in the group (last known or current position):

1. Mr. Jinghu Li 2004-2005 (student transferred to UIC in 2005)
2. Dr. Zhao Wang 2005-2010 (last known position: FDA officer)
3. Dr. Jianjun Chen 2006-2011 (last known position: Professor at South Medical Univ., China)
4. Ms. Gorgina Nabil 2012-2015 (M.S. degree, last known position: Pharmacist in Wisconsin)
5. Dr. Jin Wang 2010-2015 (last known position: AbbVie, Inc.)
6. Dr. Min Xiao 2010-2015 (last known position: Computer Scientist)
7. Mr. Xiaolin Wu 2015-2016 (M.S. degree, last known position: Google, Inc.)
8. Ms Rachel Ann Ness 2015-2017 PharmD student (Pharmacist)
9. Dr. Zongtao Lin 2012-2017, PhD student (Postdoc at U Penn; current: Assistant Professor, Rutgers University)
10. Dr. Qinghui Wang 2014-2017 PhD student (postdoc at Cornell University Medical School; postdoc in MSKCC, New York; Staff scientist: UCSF)
11. Mr. Brandon Bumbaca 2017-2018, MS student.
12. Dr. Kinsie Arnst 2014-2018, PhD student (postdoc at UT Southwestern; last known position Applicant Scientist at Biotek)
13. Dr. Shanshan Deng 2016-2020, PhD student (postdoc at UC San Francisco)
14. Dr. Hanxuan (Luke) Li 2017-2023, PhD student (postdoc at UNC Chapel Hill)
15. Dr. Najah Albadari 2017-2023, PhD student (faculty in Saudi)
16. Dr. Jiaxing Wang 2019-2024, PhD student (postdoc at Columbia University)
17. Dr. Rui Wang 2019-2024, PhD student (return to Asia)
18. Dr. Kelli Adeleye 2020-2025, PhD student

Current graduate students in the group and Chair of the graduate student thesis committee:

1. Ms. Shelby Wendell 2022-present, PhD student
2. Mr. Mir Shahriar Kamal 2023-present, PhD student
3. Ms. Lily Ann Waltz 2024-present, PhD student

4. Ms. Sara Sultana 2025-present, PhD student

Serving as a thesis committee member for students in other labs

1. Dr. Bin Fang 2003-2006
2. Mr. Jin Xu 2005-2007
3. Dr. Engy Marhous 2006-2009
4. Dr. Li Chen 2005-2009
5. Dr. Kui Zeng 2005-2010
6. Dr. Josh Brown 2005-2010
7. Dr. Renuka Gupte 2005-2011
8. Dr. Steve Gurley 2005-2010
9. Dr. Ningning Yang 2008-2011
10. Dr. Feng Li 2008-2011
11. Mr. Les Stuart 2008-2010
12. Dr. Chikezie Madu 2008-2012
13. Dr. Jerrod Scarborough 2010-2012
14. Dr. Shan Sun 2009-2015
15. Dr. Bret Koertge 2010-2015
17. Dr. Cheng Tian 2016-2019
18. Dr. Mohammad Arifur Rahman 2016-2019
19. Dr. Pallabita Chowdhury 2017-2020
20. Dr. Sanjana Haque 2016-2020
21. Dr. Elham Hatami 2019-2020
22. Dr. Chidi Zacheaus 2018-2022
23. Dr. Fatemeh Keramatnia 2019-2021
24. Dr. Madison N Sluter 2020-2023
25. Dr. Ruida Hou 2020-2023
26. Dr. Damilola Oluwalana 2021-2024, co-Mentor with Dr. Tiffany Seagroves
27. Dr. Nelufar Yasmen 2022-2024
28. Dr. Jingwen Zhu 2023-2024
29. Mr. Md Abdullah Al Mamun 2024-present, PhD student
30. Ms. Rima Patel 2025-present, PhD student
31. Ms. Juqian Han 2025-present, PhD student
32. Mr. Alexander Jenner 2020-present, PhD student

Summer Undergraduate or PharmD/PhD Dual Degree Rotation Students, or research volunteers:

- | | | |
|------------------------------|-----------------------------|---------------------|
| 1. Mr. Rodeck Slominski | Emory University | Summer of 2004 |
| 2. Mr. Chris Scheid | College of William and Mary | Summer of 2008 |
| 3. Ms. Ashley Vorenkamp | Louisiana University | Summer of 2010 |
| 4. Ms. Victoria Strong | Tennessee State University | Summer of 2011 |
| 5. Mr. Devaughn Reece | Tennessee Tech University | Summer of 2012 |
| 6. Ms. Whitney Bogus | Tennessee Tech University | Summer of 2013 |
| 7. Ms. Rachel Ness | PharmD/PhD rotation, UTCOP | July of 2013 |
| 8. Ms. Mariatu Sisay | PharmD/PhD rotation, UTCOP | August of 2014 |
| 9. Ms. Stacey M Thomas-Gooch | PharmD/PhD rotation, UTCOP | July of 2021 |
| 10. Ms Sara Sultan | Volunteer researcher | July 2024-July 2025 |
| 11. Ms. Lindsey Morgan | Summer Research Scholar | Summer of 2025 |

FELLOWSHIP/AWARD RECEIVED BY STUDENTS AND POSTDOCS IN THE LI GROUP

1. Dr. Zhao Wang (PhD student from 2005-2010), Alma and Hal Reagan Fellowship, \$22,000 fellowship plus \$1,000 travel/supplies, UTHSC College of Graduate Health Sciences, 2007-2008.
2. Dr. Zhao Wang (PhD student from 2005-2010), Alma and Hal Reagan Fellowship, \$22,000 fellowship plus \$1,000 travel/supplies, UTHSC College of Graduate Health Sciences, 2008-2009. Dr. Wang successfully renewed this fellowship (a maximum of two years is allowed).
3. Dr. Zhao Wang, Travel Award for AACR national meeting, University of Tennessee HSC, \$500, 2009

4. Dr. Zhao Wang, Travel Award for AAPS national meetings, University of Tennessee HSC, \$500, 2010
5. Dr. Zhao Wang, Travel Grant, 15th Pan American Society for Pigment Cell Research, 2009
6. Dr. Jianjun Chen (PhD student from 2005-2010), Travel Grant, 15th Pan American Society for Pigment Cell Research, 2009
7. Dr. Jianjun Chen (PhD student from 2005-2010), Travel Award for ACS national meetings, University of Tennessee HSC, \$500, 2010
8. Dr. Jin Wang (PhD student from 2010-2015), Alma and Hal Reagan Fellowship, \$23,000 fellowship plus student benefits, plus \$1,000 travel/supplies, 10/2012-9/2013.
9. Dr. Min Xiao (PhD student from 2010-2016), Robert Magarian Best Oral Presentation Award, 2013 MALTO medicinal chemistry meeting, Little Rock, AR, May 19-22, 2013.
10. Dr. Jin Wang (PhD student from 2010-2015), Alma and Hal Reagan Fellowship, \$21,000 fellowship plus \$1,000 travel/supplies, successful competitive renewal for an additional year of award (maximum allowable is two years), 10/2013-9/2014.
11. Mr. Qinghui Wang (PhD student from 2014-present), Robert Magarian Best Oral Presentation Award, 2016 MALTO medicinal chemistry meeting, Houston, TX, May 19-22, 2016.
12. Dr. Zongtao Lin (PhD student from 2012-2017), Alma and Hal Reagan Fellowship, \$21,000 fellowship plus student benefits, plus \$1,000 travel/supplies, 10/2016-9/2017
13. Dr. Qinghui Wang (PhD student from 2014-2017), CGHS travel award, Travel Award for ACS national meetings in San Francisco, University of Tennessee HSC, \$500, 2017
14. Dr. Zongtao Lin (PhD student from 2012-2017), “the 2016 Chinese Government Award for Outstanding Self-financed Students Abroad” award, China Scholarship Council, April 2017.
15. Dr. Zongtao Lin (PhD student from 2014-2017), Robert Magarian Best Oral Presentation Award, 2017 MALTO medicinal chemistry meeting, Monroe, LA, May 19-22, 2017.
16. Ms. Kinsie Arnst (PhD student from 2014-present), CGHS travel award, Travel Award for 2018 AACR Annual Meeting in Chicago, University of Tennessee HSC, \$500, 2018
17. Ms. Kinsie Arnst (PhD student from 2014-present), Robert Magarian Best Oral Presentation Award, 2018 MALTO medicinal chemistry meeting, Texas, May 22-24, 2018
18. Dr. Kinsie Arnst (PhD student from 2014-2018, defended on 11/21/2018), UTHSC College of Pharmacy Outstanding Graduate Student Award, Dec 18, 2018.
19. Dr. Kinsie Arnst (PhD student 2014-2018), Highlighted Trainee Author award for the July 2019 issue of Molecular Pharmacology. Her paper is also featured as the cover page figure in the issue.
20. Ms. Shanshan Deng (PhD student 2016-present), UTHSC Pharmaceutical Science Program Outstanding Graduate Student Award, Jan 7, 2020.
21. Ms. Shanshan Deng (PhD student, 2016-present), UTHSC Graduate Student Travel Award, 2020.
22. Dr. Shanshan Deng (PhD student, 2016-2020), Outstanding Student Award for Academic Excellence, awarded by the UTHSC Graduate School.
23. Dr. Vijay Kumar (postdoc) win the 4th place prize in oral presentation category during the 2021 UTHSC Annual Postdoc Research Day. In addition, Dr. Kumar is selected as one of the three travel awardees with \$1,000 travel award to attend a future ACS annual meeting.
24. Ms Najah Albadari (PhD student), **UTCop Outstanding Graduate Student Award**, 2022.
25. Ms Rui Wang (PhD student), travel grant of \$500 for attending and presenting an abstract at the 2022 AACR annual meeting.
26. Ms. Rui Wang (PhD student), awardee of the **2022 CGHS Outstanding Student in the Pharmaceutical Sciences Program**, College of Graduate Health Science, the University of Tennessee Health Science Center.
27. Dr. Vijay Kumar (postdoc) is the awardee for the **2022 Ronald F. Borne Postdoctoral Poster Presentation Award** during the 47th MALTO meeting.
28. Dr. Yang Xie (postdoc) wins the First Prize in the **2023 UTHSC Postdoc Research Day** competition.
29. Ms Kelli Hartmann (PhD student), a travel grant of \$500 for attending and presenting an abstract at the 2023 AACR annual meeting.

30. Ms Rui Wang (PhD student), a travel grant of \$500 for attending and presenting an abstract at the 2023 AACR annual meeting.
31. Mr. Jiaying Wang (PhD student), a travel grant of \$500 for attending and presenting an abstract at the 2023 ASPET annual meeting.
32. Mr. Jiaying Wang (PhD student), received the “2023 CGHS Student Success Award” in the 2023 UTHSC Graduate Research Day.
33. Ms. Kelli Hartmann (PhD student), **Robert Magarian Best Oral Presentation Award**, 2023 MALTO medicinal chemistry meeting, Houston, TX, May 22-24, 2023.
34. Ms. Kelli Hartmann (PhD student), **the 2023 Alma and Hal Reagan Fellowship**, 11/2023-10/2024.
35. Dr. Vijay Kumar (Research Associate) is the awardee for the **2024 Ronald F. Borne Postdoctoral Poster Presentation Award** during the 49th MALTO meeting. Also, this is the first time in the MALTO history since this award was established, that this award was awarded to the same researcher, as Vijay was the 2022 awardee as well, although for a different project. 5/2024.
36. Ms. Kelli Hartmann (PhD student), **the 2024 Duane D. Miller Award in Drug Discovery**, 6/2024.
37. Ms. Rui Wang (PhD student), **the 2024 Dean’s Award**, UTHSC graduate school, 5/2024.
38. Ms. Kelli Adeleye (PhD student), **the 2024 Alma and Hal Reagan Fellowship**, 11/2024-10/2025
39. Ms. Kelli Adeleye (PhD student), **Independent Research Grant** (\$5,000), UTHSC Graduate School, 9/2024-8/2025.
40. Dr. Vijay Boda (Research Associate), **the 2025 Outstanding Postdoctoral Scholar Award**, UTHSC, March 2025.
41. Dr. Vijay Boda (Research Associate), **the 2025 Gordon Research Conference Fellowship**.
42. Ms. Shelby Wandell (PhD student), **travel award** to attend the 2025 AAPS meeting.

EDITORIALS:

1. **Wei Li**, “Selective Vitamin D Receptor Modulators (SVIMS) as Potential Adjuvant Therapeutic Agents”, Editorial, **Modern Chemistry & Applications**, 1 (3):e110, **2013**.
2. **Wei Li** (Guest editor for the Theme Issue), “Drugs Targeting Tubulin Polymerization”, **Pharm Res**, 29(11): 2939-2942, **2012**.
3. **Wei Li**, “Meet Our Editorial Member”, Editorial, *Current Medicinal Chemistry*, 22(27):3109, **2015**.
4. **Wei Li**, (Guest editor for a Special Issue), “Tubulin Inhibitors”, **Molecules**, **2016**. “Tubulin Inhibitors 2021”, **Molecules**, **2020**. “Special Issue Honoring Dr. Duane D. Miller”, **Molecules**, **2020**.
5. **Guan Chen (Medical College of Wisconsin) and Wei Li**, (Co-Guest Editors for a Special Issue), “Targeted Cancer Therapy”, **Acta Pharmaceutica Sinica B**, 2018.
6. One of the guest editors, special issue “Managing cancer metastasis by tackling anticancer drug resistance”, **Frontiers in Pharmacology**, 2024
<https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1432248/full>.

BOOK CHAPTERS

1. Zhao Wang, **Wei Li***, and Duane Miller*, “Therapeutic Agents for Advanced Melanoma”, in *Melanoma-From Early Detection to Treatment*, edited by Guy Huynh Thien Duc, Intech publishing group, **2013**, ISBN 978-953-51-0961-7.
2. Jin Wang, Duane D. Miller*, and **Wei Li***, “Emerging Drug Combination Approaches in Melanoma Therapy”, in *Melanoma - Current Clinical Management and Future Therapeutics*, Edited by Mandi Murph, DOI: 10.5772/58516, ISBN 978-953-51-2036-0, **2014**.
3. Kinsie Arnst and **Wei Li***, “Targeting the Inhibitor of Apoptosis Proteins with Small Molecules: Recent Advances and Clinical Challenges”, in *Frontiers in Clinical Drug Research - Anti-Cancer Agents*, Volume 2, **2015**, DOI: 10.2174/97816810807271150201, eISBN: 9781681080727.

4. Sicheng Zhang, Duane D. Miller, and **Wei Li***, book chapter in “Essential and Toxic Trace Elements and Vitamins in Human Health”, Edited by Drs Ananda S. Prasad and George J. Brewer. **2020**.
5. Anna Bukiya, Hanxuan Li, Steven Mysiewicz, and **Wei Li**, “Common laboratory research methods for detection and quantification of cholesterol”, a book chapter in *Cholesterol*, **2022**.
6. Andrzej T. Slominski, Robert C Tuckey, Carl Jenkinson, **Wei Li**, Anton Jetten, “Chapter 6: Alternative pathways for vitamin D metabolism”, in the book "Feldman and Pike's Vitamin D", **2023**.
7. Vijay K. Boda and **Wei Li**, “TRP Channels as Drug Targets: Structural Insights and Therapeutic Relevance”, *Comprehensive Medicinal Chemistry*, 4th edition, edited by David Rotella and Simon Ward, in press, expected to be published in May **2026**.

ISSUED US PATENTS (related patents approved in other countries are not listed)

1. Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents, US 7,662,842, issued on 2/16/2010.
2. Compounds for treatment of cancer, US 8,592,465, issued on 11/26/2013 (licensed first to GTx Inc., then Aspen Parks Pharmaceuticals, Inc., before its merger with another company to become Veru Inc.).
3. Compounds for treatment of cancer, US 8,822,513, issued on 9/2/2014 (licensed to Veru Inc.).
4. Compounds for treatment of cancer, US 9,029,408, issued on 5/12/2015 (licensed to Veru Inc.).
5. Compounds for treatment of cancer, US 9,334,242, issued on 5/10/2016 (licensed to Veru Inc.).
6. Compounds for treatment of cancer, US 9,447,049, issued on 9/20/2016 (licensed to Veru Inc.).
7. Compounds for treatment of cancer, US 9,981,915, issued on 5/29/2018 (licensed to Veru Inc.).
8. Compounds for treatment of cancer, US 10,022,356, issued on 7/17/2018 (licensed to Veru Inc.).
9. Compounds for treatment of cancer, US 10,155,728, issued on 12/18/2018 (licensed to Veru Inc.).
10. Compounds for treatment of cancer, US 10,301,285, issued on 5/28/2019 (licensed to Veru Inc.).
11. Compounds for treatment of cancer, US 10,525,037, issued on 1/7/2020 (licensed to Veru Inc.).
12. Compounds for treatment of cancer, US 10,865,196, issued on 12/15/2020, (licensed to Veru).
13. Compounds for treatment of cancer, US 11,084,811, issued on 8/10/2021 (licensed to Veru).
14. Compounds for treatment of cancer, US 11,465,987, issued on 10/11/2022 (licensed to Veru Inc.).
15. Metabolically Stable Pyrimidinyl Dihydroquinoxalinones as Tubulin Polymerization Inhibitors, US 12,378,257, issued on 3/2025.

COMMENTARY OR PRODUCT REVIEWS:

1. Wei Li, “ChemBioDraw 12: Essential to my professional life”, invited commentary on ChemBioDraw 12. <http://insideinformatics.cambridgesoft.com/articles/Default.aspx?articleID=666>.
2. RuAngelie Edrada-Ebel, Angelo Fontana, Hideaki Kakeya, A. Douglas Kinghorn, Wei Li, Diana C. G. A. Pinto, Thomas E. Prisinzano, and Binghe Wang, “Winners of the 2024 Tu Youyou Award”, *Molecules*, <https://www.mdpi.com/1420-3049/30/10/2192>

PUBLISHED PEER-REVIEWED JOURNAL ARTICLES (* indicates corresponding author, reverse chronological order, ORCID 0000-0002-9522-4474). Most of them can be found in PubMed:

<http://www.ncbi.nlm.nih.gov/sites/myncbi/wei.li.11/bibliography/45414079/public/?sort=date&direction=descending>

Currently Under Revisions:

1. Ziping Liu, Tao Zhang, Wenjing Zhang, Xinxin Zhao, Yongshuai Li, Satyanarayana Pochampally, Shelby Wandell, Guannan Zhao, Shiji Song, Yaohong Wang, Lawrence Pfeffer, Duane D. Miller, Baojin Wang*, **Wei Li***, Junming Yue*, “A p53-Deficient, PTK2/cMyc-driven ovarian cancer mouse model for preclinical drug discovery”, submitted.
2. Christopher J. Clark¹, Shelby Waddell¹, Carl B. Womack, Yang Xie, Meirola A. Endraws, Cole T. Huddleston, Keiluhn D. Pulis, Joshua Thammathong, Kamil Tanas, Beari Jangir, Dejian Ma, Kevin Bicker, April M. Weissmiller*, **Wei Li***, Souvik Banerjee*, “Novel Triazoloquinoxaline-Based Tubulin

(2025)

230. Satyanarayana Pochampally, Lawrence M. Pfeffer, Gustavo A Miranda-Carboni, Macey Daniel, Jazz I James, Allana Smith, Chuan He Yang, Hannah R Kelso, Deanna N. Parke, Dong-Jin Hwang, **Wei Li**, Duane D Miller, “A Pyrimidine-Based Tubulin Inhibitor Shows Potent Anti-Glioblastoma Activity in vitro and in vivo”, *Pharmaceutics*, accepted on 12/4/2025.
229. Slominski AT, Slominski RM, Kamal M, Holick MF, Tuckey RC, Russel J. Reiter, **Li W**, Jetten AM, “Hypothesis paper: Is vitamin D signaling regulated by and does it regulate circadian rhythms”, *The FASEB Journal*, accepted on 11/25/2025.
228. “The deubiquitinase OTULIN regulates tau expression and RNA metabolism in neurons”, *Genomic Psychiatry*, accepted on 11/7/2025. **2025**.
227. Raisa I. Krutilina,[‡] Kelli L. Adeleye[‡], Hilaire Smith, Satyanarayana Pochampally, Souvik Banerjee, Damilola Oluwalana, Mir Shahriar Kamal, Duane D. Miller, **Wei Li*** and Tiffany N. Seagroves*, “Discovery of potent and brain-penetrable tubulin inhibitors that effectively suppress breast cancer brain metastasis”, *Mol Cancer Ther*, accepted, **2025**.
226. Rui Wang, Chun Cai, Shanshan Deng, Yang Xie, Satyanarayana Pochampally, David J. Hamilton, Bernd Meibohm, Evan S. Glazer, Duane D. Miller, **Wei Li***, “Anti-Mitotic Agent SB-216 Overcomes Taxane Resistance in Castration-Resistant Prostate Cancer and Exhibits Anti-Tumor Efficacy in Pancreatic Cancer”, *British J Pharmacology*. Accepted on 11/6/2025.
225. Tanya Garain, Prateek Rai, Wei Li, and Souvik Banerjee, “ATAD2 as a Cancer Target: Insights into its Structure, Functions, Mechanisms and Drug Development”, *Cancers*, accepted on 10/14/2025.
224. Chun Cai, Michael W. Spinrad, Lauren C. Gattie, Rui Wang, Mohammad Amir Afjal, Jun Yang, Nour Yadak, David Shibata, **Wei Li**, Amandeep Bajwa, and Evan S. Glazer, “Reprogramming oncogenic mitochondria in pancreatic cancer through BRD4 inhibition leads to programmatic cell death”, *J Pharm Exp Ther*, **2025**, accepted.
223. Bharti Sethi, Aditya Gupta, Qiaoyu Pan, Sohan Mahto, Ajaykumar Chittipolu, Helen Erickson, Virender Kumar, Yanfei Chen, Zhongzhi Wu, Yuxiang Dong, **Wei Li**, Donald R Ronning, Donald W Coulter, Ram I Mahato, “Lipid nanomedicine simultaneously inhibits BRD4/PI3K and MDM2/XIAP signaling pathways for effective treatment of Medulloblastoma”, *J Control Release*, **2025**; 387:114266. <https://pubmed.ncbi.nlm.nih.gov/41005742/>.
222. Rima Patel, Lily Waltz, Gemma Toogood, **Wei Li***, and Junwang Xu*, “The Role of Transient Receptor Potential Canonical3 (TRPC3) in Wound Healing”, *Journal of Cellular Physiology*, **2025**; 240:e70065, <https://doi.org/10.1002/jcp.70065>.
221. Najah Albadari, Yang Xie, Qinghui Wang, Darcie J. Miller, Judith Quadrozzi Gruntz, Michael L. Oldham, Hao Chen, Dejian Ma, Zhongzhi Wu, Duane D. Miller, and **Wei Li***, “Design and synthesis of novel 4-aryl-2-benzoyl-imidazoles as colchicine binding site inhibitors”, *Eur J Med Chem*, in press. **2025**.
220. Zhengjun Wang, Dongyi Ding, Jiaying Wang, Ling Chen, Qingming Dong, Moumita Khamrai, Yuyang Zhou, Akihiro Ishii, Kazuko Sakata, **Wei Li**, Jianyang Du, Thirumalini Vaithianathan, Fu-Ming Zhou, and Francesca-Fang Liao*, “Soluble β -Amyloid Oligomers Selectively Upregulate TRPC3 in Excitatory Neurons via Calcineurin-Coupled NFAT”, *Cells*, 14(11), **2025**. <https://www.mdpi.com/2073-4409/14/11/843>

219. Gemma W Toogood, Robin Evans, Liping Zhang, Rima Patel, Songmei Meng, Vijay K. Boda, **Wei Li** and Junwang Xu, "TRPC3 Inhibition Induces Myofibroblast Differentiation in Diabetic Dermal Fibroblasts", *Frontiers in Physiology*, **2025**, 30:16:1577118. doi: 10.3389/fphys.2025.1577118.
218. Mousumi Mandal, Md Abdullah Al Mamun, Ahmed Rakib, Santosh Kumar, Frank Park, Dong-Jin Hwang, **Wei Li**, Duane D. Miller, Udai P. Singh, "Modulation of occludin, NF- κ B, p-STAT3, and Th17 response by DJ-X-025 decreases inflammation and ameliorates experimental colitis", *Biomedicine & Pharmacotherapy*, **2025**. 185:117939. PMID: 40036995
217. Zhongzhi Wu and **Wei Li***, "A Practical and Highly Efficient Procedure for the Synthesis of the Trifluoromethylpyrazol-Derived Canonical Transient Receptor -Potential Channel (TRPC3) Inhibitor Pyr3 and Its Derivatives", *Synlett*, **2025**. In press. DOI: 10.1055/s-0043-1773516
216. Jiaying Wang, Sicheng Zhang, Vijay K. Boda, Hao Chen, Hyunseo Park, Keyur Parmar, Dejian Ma, Duane D. Miller, Bernd Meibohm, Jianyang Du, Francesca-Fang Liao, Zhongzhi Wu*, and **Wei Li***, "Discovery of a potent and selective TRPC3 antagonist with neuroprotective effects", *Bioorg. Med. Chem. (current IF=3.3)*, **2025**, 117, 118021, <https://doi.org/10.1016/j.bmc.2024.118021>.

(2024)

215. Mousumi Mandal, Ahmed Rakib, Md Abdullah Al Mamun, Dong-Jin Hwang, **Wei Li**, Duane D. Miller, Santosh Kumar, Bhupesh Singla, Park Frank, and Udai P. Singh, "DJ-X-013 modulates Th17/ myeloid-derived suppresser cells by altering NF- κ B expression to ameliorate inflammation and experimental colitis", *Biomedicine & Pharmacotherapy (current IF=6.9)*, **2024**, 179:117379. PMID: 39255739 PMCID: PMC11479677.
214. Tao Liu, Lubing Gu, Anna Mui, Zhongzhi Wu, Najah Albadari, **Wei Li***, Muxiang Zhou*, "An MDM2 degrader shows potent cytotoxicity to MDM2-overexpressing acute lymphoblastic leukemia cells with minimal toxicity to normal cells/tissues", *Cancer Letters (current IF=9.76)*, **2024**, 598:217126. PMID: 39053726 PMCID: PMC11515855. <https://doi.org/10.1016/j.canlet.2024.217126>.
213. Zhen Chen, Karin A. Vallega, Vijay K. Boda, Zihan Quan, Dongsheng Wang, Songqing Fan, Qiming Wang, Suresh S. Ramalingam, **Wei Li**, Shi-Yong Sun, "Targeting transient receptor potential melastatin-2 (TRPM2)enhances therapeutic efficacy of third generation EGFR inhibitors against EGFR mutant lung cancer", *Advanced Science (current IF=15.1)*, **2024**, 11(35):e2310126. PMID: 39044361 PMCID: PMC11425210. <https://doi.org/10.1002/advs.202310126>
212. Shelby Waddell, Guannan Zhao, Ziping Liu, Hao Chen, Wenjing Zhang, Yaohong Wang, Duane D. Miller, Junming Yue* and **Wei Li***, "VERU-111, an Orally Available Tubulin Inhibitor, Suppresses Ovarian Tumor Growth and Metastasis" is accepted in the *Journal of Pharmacology and Experimental Therapeutics (JPET, current IF=4.4)*, **2024**. 392(1):100006. PMID: 39893008 PMCID: PMC11808928. <https://jpet.aspetjournals.org/content/early/2024/06/27/jpet.124.002298>
211. K.L. Adeleye, A.R. Li, Y. Xie, S. Pochampally, D. Hamilton, F. Garcia-Godoy, D.D. Miller, and **W. Li***, "Novel Antimitotic Agent SP-1-39 Inhibits Head and Neck Squamous Cell Carcinoma", *Journal of Dental Research (current 2-year IF=8.9)*, 103(9):926-936, **2024**. PMID: 39101715 PMCID: PMC11465348. <https://doi.org/10.1177/00220345241261982>
210. Andrzej T. Slominski, Tae-Kang Kim, Zorica Janjetovic, Radomir M. Slominski, **Wei Li**, Anton M. Jetten, Arup K. Indra, Rebecca S. Mason, Robert C. Tuckey, "Biological effects of CYP11A1-derived vitamin D and lumisterol metabolites in the skin", *Journal of Investigative Dermatology, (current IF=6.5)*. 144(10):2145-2161, **2024**. <https://doi.org/10.1016/j.jid.2024.04.022>.
209. Zahr T, Boda VK, Ge J, Yu L, Wu Z, Que J*, **Li W***, Qiang L*. Small molecule conjugates with selective estrogen receptor β agonism promote anti-aging benefits in metabolism and skin recovery. *Acta Pharm Sin B. (current IF=14.5)*, **2024**;14(5):2137-52. PubMed PMID: 38799642; PMCID: PMC11119546.
- 208*. (Editorial) Wu E*, Wu Z, Yang CY, Qi D, Hu X, **Li W***. Editorial: Managing cancer metastasis by tackling anticancer drug resistance. *Front Pharmacol. (current IF=7.4)*, **2024**;15:1432248. PubMed PMID: 38915467; PMCID: PMC11194419.

207. Wang W, Albadari N, Du Y, Fowler JF, Sang HT, Xian W, McKeon F, **Li W**, Zhou J, Zhang R. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future. *Pharmacol Rev.* (current IF=21.1), **2024**;76(3):414-53. PubMed PMID: 38697854; PMCID: PMC11068841.
206. Silva-Cardoso GK, Boda VK, **Li W**, N'Gouemo P. Inhibition of TRPC3 channels suppresses seizure susceptibility in the genetically-epilepsy prone rats. *Eur J Pharmacol* (current IF=5.0). **2024**, 977:176722. PubMed PMID: 38851562.
205. Oluwalana D, Adeleye KL, Krutilina RI, Chen H, Playa H, Deng S, Parke DN, Abernathy J, Middleton L, Cullom A, Thalluri B, Ma D, Meibohm B, Miller DD, Seagroves TN*, **Li W***. Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer. *Cancer Lett.* (current IF=9.7), **2024**;597:217011. PubMed PMID: 38849011.
204. Lei ZN, Albadari N, Teng QX, Rahman H, Wang JQ, Wu Z, Ma D, Ambudkar SV, Wurlpel JND, Pan Y, **Li W***, Chen ZS*. ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C. *Drug Resist Updat.* (current IF=24.3), **2024**;73:101065. PubMed PMID: 38367548.
203. Janjetovic Z, Qayyum S, Reddy SB, Podgorska E, Scott SG, Szpotan J, Mobley AA, **Li W**, Boda VK, Ravichandran S, Tuckey RC, Jetten AM, Slominski AT. Novel Vitamin D3 Hydroxymetabolites Require Involvement of the Vitamin D Receptor or Retinoic Acid-Related Orphan Receptors for Their Antifibrogenic Activities in Human Fibroblasts. *Cells.* (current IF=6.0), **2024**;13(3). PubMed PMID: 38334631; PMCID: PMC10854953.
202. Boda VK, Yasmen N, Jiang J, **Li W***. Pathophysiological significance and modulation of the transient receptor potential canonical 3 ion channel. *Med Res Rev.* (current IF=13.3), **2024**. PubMed PMID: 38715347.

(2023)

201. Zhousheng Xiao, Li Cao, Micholas Smith, Hanxuan Li, **Wei Li**, Jeremy Smith, and L. Darryl Quarles, "Genetic interactions between Polycystin-1 and TAZ in osteoblasts define a novel mechanosensing mechanism regulating bone formation in mice", *Bone Research*, **11**, **57**, **2023**, current IF=13.362, <https://doi.org/10.1038/s41413-023-00295-4>.
200. Wei Wang, Yi Du, Sayantap Datta, Fowler, Josef F, Hannah Sang, Najah Ghazi Albadari, **Wei Li**, Jennifer Foster, Ruiwen Zhang, "Targeting the MYCN-MDM2 Pathways for Cancer Therapy: Are They Druggable?", *Genes & Diseases*, current IF=7.4, **2023**, accepted on 9/27/2023.
199. Zhijia Wang#, Hanxuan Li#, Lantu Gou, **Wei Li***, Yuxi Wang*, "Antibody–drug conjugates: Recent advances in payloads", *Acta Pharmaceutica Sinica B*, **13(10)**, **4025-4059**, **2023**. Current IF=14.9, <https://doi.org/10.1016/j.apsb.2023.06.015>. #Zhijia Wang and Hanxuan Li are co-first authors.
198. Yang Xie, Ruida Hou, Kelli L. Hartman, Jianxiong Jiang, Zhongzhi Wu*, **Wei Li***, "JW-1-283 inhibits melanoma tumor growth via stabilization of the p53 pathway", *Genes & Diseases*, current IF=7.4, **2023**, accepted on 6/20/2023.
197. Najah Albadari#, Yang Xie#, Tao Liu, Rui Wang, Lubing Gu, Muxiang Zhou*, Zhongzhi Wu*, **Wei Li***, "Synthesis and biological evaluation of dual MDM2/XIAP inhibitors based on the tetrahydroquinoline scaffold", *Eur J Med Chem*, current IF=7.1, **2023**, 255:115423. PMID: 37130471 PMCID: PMC10246915. <https://pubmed.ncbi.nlm.nih.gov/37130471/>. #Najah and Yang are co-first authors.
196. Satyanarayana Pochampally, Kelli L Hartman, Rui Wang, Jiaying Wang, Mi-Kyung Yun, Keyur Parmar, Hyunseo Park, Bernd Meibohm, Stephen W. White, **Wei Li ***, Duane D. Miller*, "Design, Synthesis, and Biological Evaluation of Pyrimidine Dihydroquinoxalinone Derivatives as Tubulin Colchicine Site Binding

Agents that Displayed Potent Anticancer Activity Both In Vitro and In Vivo”, *ACS Pharmacology & Translational Science*, current IF=6.04, **2023**, 6(4):526-545

195. Najah Albadari and **Wei Li***, “Survivin Small Molecules Inhibitors: Recent Advances and Challenges”, *Molecules*, current IF=4.9, **2023**, 28(3):1376
194. Deng S, Banerjee S, Chen H, Pochampally S, Wang Y, Yun MK, White SW, Parmar K, Meibohm B, Hartman KL, Wu Z, Miller DD, **Li W***, “SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis”, *Cancer Letters*, current IF=9.8, **2023**, 555:216046.

(2022)

193. Liu T, Gu L, Wu Z, Albadari N, **Li W**, Zhou M, “MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma”, *Frontiers in Oncology*, **2022**, 12:1058726.
192. Wang J, Miller DD, **Li W.***, “Molecular interactions at the colchicine binding site in tubulin: An X-ray crystallography perspective”, *Drug Discov Today*, **2022**, 27(3):759-776.
191. Raisa I. Krutilina, Kelli L. Hartman, Damilola Oluwalana, Hilaire C. Playa, Deanna N. Parke, Hao Chen, Duane D. Miller, **Wei Li*** and Tiffany N. Seagroves*, “Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+ Breast Cancer and Metastasis”, *Cancers*, **2022**, 14(21):5336..
190. Huijun Guo, Wenjing Zhang, Jiaying Wang, Guannan Zhao, Yaohong Wang, Bing-Mei Zhu, Peixin Dong, Hidemichi Watari, Baojin Wang, **Wei Li**, Gabor Tigyi, Junming Yue, “Cryptotanshinone inhibits ovarian tumor growth and metastasis by degrading c-Myc and attenuating the FAK signaling pathway”, *Frontiers Cell and Developmental Biology* (current IF=6.68), accepted on 9/8/2022.
189. Rajan S. Bhattarai, Virender Kumar, Jitender Bariwal, Hao Chen, Shanshan Deng, **Wei Li** and Ram I Mahato, “pH-sensitive Nanomedicine of Novel Tubulin Polymerization Inhibitor to Lung Metastatic Melanoma”, *Journal of Controlled Release* (current IF=11.4), 2022, accepted on 7/22/2022.
188. Ying Yu, **Wei Li**, and Jianxiong Jiang, “TRPC channels as emerging targets for seizure disorders”, *Trends in Pharmacological Sciences* (current IF=17.6), 2022, in press, PMID: 35840362
187. Alexandria V. Slayden, Christy L. Dyer, Dejian Ma, **Wei Li**, Anna N. Bukiya, Abby L. Parrill, Alex M Dopico, “Discovery of agonist-antagonist pairs for the modulation of Ca²⁺ and voltage-gated K⁺ channels of large conductance that contain beta1 subunits”, *Bioorganic & Medicinal Chemistry*, in press, **2022**.
186. Wei Dong; Bradley C. Postlethwaite; Patricia A. Wheller; David Brand; Yan Jiao; **Wei Li**; Linda K Myers; Weikuan Gu, “Beta-caryophyllene prevents the defects in trabecular bone caused by Vitamin D deficiency through pathways instated by increased expression of klotho”, *Bone & Joint Research*, in press, **2022**.
185. Andrzej T Slominski*, Anna A Brożyna*, Tae-Kang Kim, Mahmoud M Elsayed, Zorica Janjetovic, Shariq Qayyum, Radomir M. Slominski, Allen S.W. Oak, Changzhao Li, Ewa Podgorska, **Wei Li**, Anton M Jetten, Robert C Tuckey, Edith K Y Tang, Craig Elmets, Mohammad Athar, “CYP11A1-derived vitamin D hydroxyderivatives as candidates for therapy of basal and squamous cell carcinomas”, *International of Oncology*, in press, **2022**.
184. S Deng, RI Krutilina, KL Hartman, H Chen, DN Parke, R Wang, F Mahmud, D Ma, PB Lukka, B Meibohm, TN Seagroves, DD Miller, and **W Li***, “Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer”, *Mol Cancer Ther*, **2022**, in press, doi: 10.1158/1535-7163.MCT-21-0899

183. Marwa M. Nagib, Sicheng Zhang, Nelufar Yasmen, Lexiao Li, Ruida Hou, Ying Yu, Vijay Kumar, Zhongzhi Wu, **Wei Li**, Jianxiong Jiang, "Inhibition of TRPC3 channels by a novel pyrazole compound confers antiseizure effects", *Epilepsia*, **2022**, accepted on 1/31/2022.
182. Bhuniya, Rajib; Yuan, Xinrui; Bai, Longchuan; Howie, Kathryn; Wang, Rui; **Li, Wei**; Park, Frank; Yang, Chao-Yie, "Design, Synthesis and Biological Evaluation of Apcin-Based CDC20 Inhibitors", *ACS Med Chem Lett.* **2022**, 13(2):188–195.
181. Monica L. Brown Lobbins, Andrzej T. Slominski, Karen A. Hasty, Sicheng Zhang, Duane D. Miller, **Wei Li**, Tae-Kang Kim, Zorica Janjetovic, Robert C. Tuckey, Imara-Safi O. Scott, Linda K. Myers,* and Arnold E. Postlethwaite, "Modulation by 17,20S(OH)2pD of Fibrosis-Related Mediators in Dermal Fibroblast Lines from Healthy Donors and from Patients with Systemic Sclerosis", *Int. J. Mol. Sci.* **2022**, 23(1), 367; <https://doi.org/10.3390/ijms23010367>

(2021)

180. Linda K. Myers, Michael Winstead, John D. Kee, Jeoungeun J. Park, Sicheng Zhang, **Wei Li**, Ae-Kyung Yi, John M. Stuart, Edward F. Rosloniec, David D. Brand, Robert C. Tuckey, Andrzej T. Slominski, Arnold E. Postlethwaite, and Andrew H. Kang, "1,25-Dihydroxyvitamin D3 and 20-Hydroxyvitamin D3 Upregulate LAIR-1 and Attenuate Collagen Induced Arthritis", *Int J Mol Sci.* **2021**, 22(24): 13342. <https://doi.org/10.3390/ijms222413342>
179. Zhang S, Miller DD, **Li W***, "Non-Musculoskeletal Benefits of Vitamin D beyond the Musculoskeletal System", *Int J Mol Sci.* **2021**, 22(4):2128.
178. Wu Z, Gu L, Zhang S, Liu T, Lukka PB, Meibohm B, Bollinger JC, Zhou M, **Li W***, "Discovery of N-(3,4-Dimethylphenyl)-4-(4-isobutylphenyl)-2,3,3a,4,5,9b-hexahydrofuro[3,2-c]quinoline-8-sulfonamide as a Potent Dual MDM2/XIAP Inhibitor", *J Med Chem.* **2021**, 64(4):1930-1950
177. Cui H, Wang Q, Miller DD, **Li W***, "The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma", *Front Pharmacol.* **2021**, 12:637098
176. Zhang S, Romero LO, Deng S, Wang J, Li Y, Yang L, Hamilton DJ, Miller DD, Liao FF, Cordero-Morales JF, Wu Z, **Li W***, "Discovery of a Highly Selective and Potent TRPC3 Inhibitor with High Metabolic Stability and Low Toxicity", *ACS Med Chem Lett.* **2021**, 12(4):572-578.
175. Shuai W, Wang G, Zhang Y, Bu F, Zhang S, Miller DD, **Li W***, Ouyang L*, Wang Y*, "Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy", *J Med Chem.* **2021**, 64(12):7963-7990.
174. Postlethwaite AE, Tuckey RC, Kim TK, **Li W**, Bhattacharya SK, Myers LK, Brand DD, Slominski AT, "20S-Hydroxyvitamin D3, a Secosteroid Produced in Humans, Is Anti-Inflammatory and Inhibits Murine Autoimmune Arthritis", *Front Immunol.* **2021**, 12:678487.
173. Wang B, Li H, Zhao X, Zhang W, Zhao G, Wu Z, Zhang R, Dong P, Watari H, Tigyi G, **Li W***, Yue J.*, "A Luminacin D Analog HL142 Inhibits Ovarian Tumor Growth and Metastasis by Reversing EMT and Attenuating the TGFβ and FAK Pathways", *J Cancer.* **2021**, 12(18):5654-5663
172. Albadari N, Deng S, Chen H, Zhao G, Yue J, Zhang S, Miller DD, Wu Z, **Li W.***, "Synthesis and biological evaluation of selective survivin inhibitors derived from the MX-106 hydroxyquinoline scaffold", *Eur J Med Chem.* **2021**, 224:113719.
171. Chen J, Li L, Liu J, Yuan S, Liao W, Slominski AT, **Li W**, Żmijewski MA, Chen J, "Discovery of novel 3-hydroxyandrost-5,7-Diene-17-Carboxylic acid derivatives as anti-inflammatory bowel diseases (IBD) agents", *Eur J Med Chem.* **2021**, 220:113468
170. Reddi KK, Li H, **Li W***, Tetali SD*, "Berberine, A Phytoalkaloid, Inhibits Inflammatory Response Induced by LPS through NF-Kappaβ Pathway: Possible Involvement of the IKKα", *Molecules.* **2021**, 26(16):4733.
169. Brown Lobbins ML, Scott IO, Slominski AT, Hasty KA, Zhang S, Miller DD, **Li W**, Kim TK, Janjetovic Z, Patel TS, Myers LK, Postlethwaite AE, "17,20S(OH)2pD Can Prevent the Development of Skin Fibrosis in the Bleomycin-Induced Scleroderma Mouse Model", *Int J Mol Sci.* **2021**, 22(16):8926.

168. Chen H, Deng S, Albadari N, Yun MK, Zhang S, Li Y, Ma D, Parke DN, Yang L, Seagroves TN, White SW, Miller DD, **Li W.***, “Design, Synthesis, and Biological Evaluation of Stable Colchicine-Binding Site Tubulin Inhibitors 6-Aryl-2-benzoyl-pyridines as Potential Anticancer Agents.”, *J Med Chem.* **2021**, 64(16):12049-12074.
167. Li H, Ibrahim MM, Chen H, **Li W.*** Jablonski MM.*, “In Silico Screening and In Vivo Evaluation of Potential CACNA2D1 Antagonists as Intraocular Pressure-Reducing Agents in Glaucoma Therapy”, *Pharmaceuticals.* **2021**, 14(9):887
166. Banerjee S, Mahmud F, Deng S, Ma L, Yun MK, Fakayode SO, Arnst KE, Yang L, Chen H, Wu Z, Lukka PB, Parmar K, Meibohm B, White SW, Wang Y, **Li W***, Miller DD.*, “X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor” *J Med Chem*, **2021**, 64(17):13072-13095
165. Rajan Sharma Bhattarai, Virender Kumar, Svetlana Romanova, Jitender Bariwal, Hao Chen, Shanshan Deng, Tatiana Bronich, **Wei Li***, and Ram I Mahato*, “Nanoformulation Design and Therapeutic Potential of Novel Tubulin Inhibitor in Pancreatic Cancer”, *J Controlled Release*, **2021**, 329:585-597 .
164. Hanxuan Li, Zhousheng Xiao, L. Darryl Quarles,* and **Wei Li,*** “Osteoporosis: Mechanism, Molecular Target, and Current Status on Drug Development”, *Current Medicinal Chemistry*, **2021**;28(8):1489-1507.

(2020)

163. Foyez Mahmud, Shanshan Deng, Hao Chen, Duane D. Miller, **Wei Li***, “Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer”, *Cancer Letters*, 495:76-88, **2020**.
162. Jingxuan Chen, Ziyu Tang, Andrzej T. Slominski, **Wei Li**, Michał A Żmijewski, Yao Liu*, Jianjun Chen*, “Vitamin D and its analogs as anticancer and anti-inflammatory agents”, *European Journal of Medicinal Chemistry*, 207:112738, **2020**.
161. Souvik Banerjee, Derek D. Norman, Shanshan Deng, Sayo Fakayode, Sue Chin Lee, Abby L. Parrill, **Wei Li**, Duane D. Miller, Gabor J. Tigyi, “Molecular Modelling Guided Design, Synthesis and QSAR Analysis of New Small Molecule Non-Lipid Autotaxin Inhibitors”, *Bioorganic Chemistry*, 103:104188, **2020**.
160. Anyamanee Chaiprasongsuk, Zorica Janjetovic, Tae-Kang Kim, Robert C. Tuckey, **Wei Li**, Chander Raman, Uraivan Panich, Andrzej T. Slominski, “CYP11A1-derived vitamin D3 products protect against UVB-induced inflammation and promote keratinocytes differentiation”, *Free Radical Biology and Medicine*, 155:87-98, **2020**.
159. Shanshan Deng, Raisa I Krutilina, Qinghui Wang, Zongtao Lin, Deanna N. Parke, Hilaire C. Playa, Hao Chen, Duane D. Miller, Tiffany N. Seagroves*, **Wei Li***, “An orally available tubulin inhibitor, VERU-111, suppresses triple-negative breast cancer tumor growth and metastasis and bypasses taxane resistance”, *Mol Cancer Ther*, 19(2):348-363, **2020**. Selected as the cover page figure for the Feb'2020 issue.
158. Jean Jacques Vanden Eynde, Arduino A. Mangoni, Jarkko Rautio, Jérôme Leprince, Yasu-Taka Azuma, Alfonso T. García-Sosa , Christopher Hulme, Josef Jampilek , Rafik Karaman, **Wei Li**, Paula A. C. Gomes, Dimitra Hadjipavlou-Litina, Raaele Capasso, Athina Geronikaki, Laura Cerchia, Jean-Marc Sabatier, Rino Ragno, Tiziano Tuccinardi, Andrea Trabocchi, Jean-Yves Winum, F. Javier Luque, Katalin Prokai-Tatrai, Mariana Spetea, Michael Gütschow, Ivan Kosalece, Catherine Guillou, M. Helena Vasconcelos, George Kokotos, Giulio Rastelli, Maria Emília de Sousa, Clementina Manera, Sandra Gemma, Stefano Mangani, Carlo Siciliano, Stefania Galdiero, Hong Liu, Peter J. H. Scott, Cristóbal de los Ríos, Luigi A. Agrofoglio, Simona Collina, Rita C. Guedes and Diego Muñoz-Torrero, “Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–6”, *Molecules*, 25, 119, **(2020)**.
157. Hao Chen, Shanshan Deng, Yuxi Wang, Najah Albadari, Gyanendra Kumar, Dejian Ma, Weimin Li, Stephen W. White, Duane D. Miller, and **Wei Li***, “Structure Activity Relationships Study of Novel 6 Aryl-2-Benzoyl-Pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties”, *J Med Chem*, 63(2):827-846, **2020**.
156. Vivek K Kashyap, Nirnoy Dan, Neeraj Chauhan, Qinghai Wang, Saini Setua, Prashanth K B Nagesh, Shabnam Malik, Vivek Batra, Zubair Bin Hafeez; Murali M. Yallapu, Duane D. Miller, **Wei Li**, Bilal B Hafeez, Meena

Jaggi, Subhash Chauhan, “VERU-111 suppresses tumor growth and metastatic phenotypes of cervical cancer cells through the activation of p53 signaling pathway”, *Cancer Letters*, 470:64-74, **2020**.

155. Slominski AT, Kim TK, Kleszczyński K, Semak I, Janjetovic Z, Sweatman T, Skobowiat C, Steketee JD, Lin Z, Postlethwaite A, **Li W**, Reiter RJ, Tobin DJ, “Characterization of Serotonin and N-acetylserotonin Systems in the Human Epidermis and Skin Cells”, *J Pineal Res*, 68(2):e12626, **2020**. PMID: 31770455
154. Hongmei Cui, Kinsie Arnst, Duane D Miller, and **Wei Li***, “Recent advances on elucidating paclitaxel resistance mechanisms in non-small cell lung cancer and strategies to overcome drug resistance”, *Curr Med Chem*, **2020**;27(39):6573-6595.

(2019)

153. Arnst KE, Banerjee S, Wang Y, Chen H, Li Y, Yang L, Li W, Miller DD, **Li W***, “X-Ray Crystal Structure Guided Discovery and Antitumor Efficacy of Dihydroquinoxalinone as Potent Tubulin Polymerization Inhibitors”, *ACS Chem Biol*, 14(12):2810-2821, **2019**. PMID: 31714738.
152. Guannan Zhao, Qinghui Wang, Zhongzhi Wu, Xinchun Tian, Huan Yan, Baojin wang, Peixin Dong, Hidemichi Watari, Lawrence M Pfeiffer, Yuqi Guo, **Wei Li***, and Junming Yue*, “Ovarian primary and metastatic tumors suppressed by survivin knockout or a novel survivin inhibitor”, *Mol Cancer Ther*, **2019**, 18(12):2233-2245.
151. Jitender Bariwal, Virender Kumar, Hao Chen, Rajan Bhattarai, Peng Yang, **Wei Li*** and Ram I Mahato*, “Nanoparticulate Delivery of a Potent Microtubule Inhibitor for Metastatic Melanoma Treatment”, *Journal of Controlled Release*, 309:231-243, **2019**.
150. Wang, Qinghui; Arnst, Kinsie; Wang, Yuxi; Kumar, Gyanendra; Ma, Dejian; White, Stephen; Miller, Duane; Li, Weimin; **Li, Wei***, “Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin”, *J Med Chem*, **2019**, 62(14):6734-6750.
149. Albadari N, Deng S, **Li W***, “The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy”, *Expert Opin Drug Discov.*, 14(7):667-682 (**2019**). PMID: 31070059.
148. Arnst KE, Wang Y, Lei ZN, Hwang DJ, Kumar G, Ma D, Parke DN, Chen Q, Yang J, White SW, Seagroves TN, Chen ZS, Miller DD, **Li W***, “Colchicine binding site agent DJ95 overcomes drug resistance and exhibits antitumor efficacy”, *Mol Pharmacol*, 96(1):73-89 (**2019**). PMID: 31043459, DOI: 10.1124/mol.118.114801. Selected as cover page figure and Dr. Arnst was selected as the Highlighted Trainee Author, both will appear in the July’2019 issue.
147. Anyamanee Chaiprasongsuk, Zorica Janjetovic, Tae-Kang Kim, Stuart G. Jarrett, John A. D’Orazio, Michael F. Holick, Edith K. Y. Tang, Robert C. Tuckey, Uraivan Panich, **Wei Li**, Andrzej T. Slominski, “Protective effects of novel derivatives of vitamin D3 and lumisterol against UVB-induced damage in human keratinocytes involve activation of Nrf2 and p53 defense mechanisms”, *Redox Biology*, accepted on 4/15/2019.
146. Ruinan Yang[#], Hao Chen[#], Dawei Guo, Yuxiang Dong, Duane D. Miller, **Wei Li***, and Ram I. Mahato*, “Polymeric Micellar Delivery of Novel Microtubule Destabilizer and Hedgehog Signaling Inhibitor for Treating Chemoresistant Prostate Cancer”, *J Pharm Exp Ther*, **2019**, 370(3):864-875. (Yang and Chen are equal first authors. Li and Mahato are co-corresponding authors)
145. Kinsie E Arnst[#], Souvik Banerjee[#], Hao Chen, Shanshan Deng, Dong-Jin Hwang, **Wei Li***, and Duane D Miller*, “Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy”, *Med. Res. Rev.*, **2019**, 39(4):1398-1426. (Kinsie Arnst and Souvik Banerjee are equal first authors; Wei Li and Duane Miller are co-corresponding authors).
144. Vivek K Kashyap; Qinghui Wang; Saini Setua; Prashanth KB Nagesh; Neeraj Chauhan; Sonam Kumari; Pallabita Chowdhury; Duane D Miller; Murali M Yallapu; **Wei Li**; Meena Jaggi Jaggi; Bilal B Hafeez; Subhash C. Chauhan, “Therapeutic efficacy of a novel β III/ β IV-tubulin inhibitor (VERU-111) in pancreatic cancer”, *J. Experimental & Clinical Cancer Research*, 38(1):29. (**2019**).

(2018)

143. Arduino A Mangoni, Catherine Guillou, Jean Jacques Vanden Eynde, Christopher Hulme, Josef Jampilek, **Wei Li**, Katalin Prokai-Tatrai, Jarkko Rautio, Simona Collina, Tiziano Tuccinardi, Maria Emilia de Sousa, Jean-Marc Sabatier, Stefania Galdiero, Rafik Karaman, George Kokotos, Giangiacomo Torri, F. Javier Luque, M. Helena Vasconcelos, Dimitra Hadjipavlou-Litina, Carlo Siciliano, Michael Gütschow, Rino Ragno, Paula A. C. Gomes, and Diego Muñoz-Torrero, "Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-4", *Molecules*, 24 (1):E130. (2018), <http://www.mdpi.com/1420-3049/24/1/130/pdf>
142. Baojin Wang, Xia Li, Guannan Zhao, Huan Yan, Yuqi Guo, Peixin Dong, Hidemichi Watari, Michelle Sims, **Wei Li**, Lawrence M. Pfeffer, Junming Yue, "miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGF β pathway", *J. Experimental & Clinical Cancer Research*, accepted on 9/9/2018. (2018).
141. Qinghui Wang, Kinsie E. Arnst, Yuxi Wang, Gyanendra Kumar, Dejian Ma, Hao Chen, Jinliang Yang, Stephen W. White, Duane D. Miller, **Wei Li***, "Structural modification of the 3,4,5-trimethoxyphenyl moiety in the tubulin inhibitor VERU-111 leads to improved antiproliferative activities", *J. Med. Chem.*, accepted on 8/20/2018, (2018).
140. Wei Wang, Bo Zhang, Arul M Mani, Zhongzhi Wu, Yu Fan, **Wei Li** and Zhao-Hui Wu, "Survivin inhibitors mitigate chemotherapeutic resistance in breast cancer cells by suppressing genotoxic NF-kappaB activation", *J. Pharm. Exp. Ther.*, 366(1):184-193, PMID: 29735611, PMCID: Journal-in-progress (2018).
139. Brandon Bumbaca and **Wei Li***, "Taxane Resistance in Castration-Resistant Prostate Cancer: Mechanisms and Therapeutic Strategies", *Acta Pharmaceutica Sinica B*, 8(4), 518-529, 2018.
138. Peng Zhang; Guannan Zhao; Liang Ji; Jinggang Yin; Lu Lu; Guomin Zhou; **Wei Li**; Edward Chaum; Junming Yue, "Loss of survivin results in inhibition of epithelial to mesenchymal transition in retinal pigment epithelial cells by attenuating the TGF β pathway", *Biochemical and Biophysical Research Communications*, accepted on 3/5/2018.
137. Qinghui Wang, Kinsie E. Arnst, Yi Xue, Zi-Ning Lei, Zhe-Sheng Chen, Duane D. Miller, **Wei Li***, "Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors", *Eur. J. Med. Chem.*, in press, <https://doi.org/10.1016/j.ejmech.2018.02.045>, 2018.
136. Souvik Banerjee^{‡,1}, Kinsie E. Arnst^{‡,1}, Yuxi Wang^{‡,2}, Gyanendra Kumar, Shanshan Deng, Lei Yang, Guobo Li, Jinliang Yang, Stephen W. White, **Wei Li***, and **Duane D. Miller***, "Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Anti-Tumor Efficacy", *J. Med. Chem.*, PMID: 29406710, DOI: 10.1021/acs.jmedchem.7b01858, (2018).
135. Robert C. Tuckey, **Wei Li**, Dejian Ma, Chloe Y. S. Cheng, Katie M. Wang, Tae-Kang Kim, Saowanee Jeayeng, and Andrzej T. Slominski, "CYP27A1 acts on the pre-vitamin D3 photoproduct, lumisterol, producing biologically active hydroxy-metabolites", *Journal of Steroid Biochemistry & Molecular Biology*. Accepted on 2/12/2018, (2018).
134. Zongtao Lin, Srinivasa R. Marepally, Emily S. Y. Goh, Chloe Y. S. Cheng, Zorica Janjetovic, Tae-Kang Kim, Duane D. Miller, Arnold E. Postlethwaite, Andrzej T. Slominski, Robert C. Tuckey, Carole Peluso-Iltis, Natacha Rochel*, **Wei Li***, "Investigation of 20S-hydroxyvitamin D3 analogs and their 1 α -OH derivatives as potent vitamin D receptor agonists with anti-inflammatory activities", *Sci. Rep.*, 8:1478, (2018), DOI:10.1038/s41598-018-19183-7.

(2017)

133. Kinsie Arnst, Yuxi Wang, Dong-Jin Hwang, Yi Xue, Terry Costello, David Hamilton, Qiang Chen, Jinliang Yang, Frank Park, James T. Dalton, Duane D. Miller*, and **Wei Li***, "A potent, metabolically stable tubulin inhibitor targets the colchicine binding site and overcomes paclitaxel drug resistance", *Cancer Research*, in press, DOI: 10.1158/0008-5472.CAN-17-0577, 2017.
132. Zhousheng Xiao, Jerome Baudry, Li Cao, Jinsong Huang, Hao Chen, Charles R. Yates, **Wei Li**, Christopher M. Waters, Jeremy C. Smith, L. Darryl Quarles, "Polycystin-1 interacts with TAZ to stimulate osteoblastogenesis and inhibit adipogenesis", *Journal of Clinical Investigation*, accepted on 10/17/2017.
131. Guannan Zhao, Qinghui Wang, Qingqing Gu, Wenan Qiang, Jianjun Wei, Peixin Dong, Hidemichi Watari, **Wei Li***, and Junming Yue*, "Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits

epithelial to mesenchymal transition in ovarian cancer cells”, *Oncotarget*, 8(55): 94666–94680, **2017**, PMID: 29212257 PMCID: PMC5706903 DOI: 10.18632/oncotarget.21863.

130. Mohammad A. Rahman, Narasimha M. Midde, Xiaoxin Wu, **Wei Li**, and Santosh Kumar, “Kinetic characterizations of diallyl sulfide analogs for their novel role as CYP2E1 enzyme inhibitors”, *Pharmacology Research & Perspectives*, 2017, accepted.
129. Zongtao Lin, Hao Chen, Anna Y. Belorusova, John C. Bollinger, Edith K.Y. Tang, Zorica Janjetovic, Tae-Kang Kim, Zhongzhi Wu, Duane D. Miller, Andrzej T. Slominski, Arnold E. Postlethwaite, Robert C. Tuckey, Natacha Rochel, and **Wei Li***, “ $1\alpha,20S$ -Dihydroxyvitamin D3 Interacts with Vitamin D Receptor: Crystal Structure and Route of Chemical Synthesis”, *Sci. Rep.*, 7(1):10193. 2017, PMID: 28860545 PMCID: PMC5579064.
128. Andrzej T. Slominski*, Tae-Kang Kim, Judith V. Hobrath, Zorica Janjetovic, Allen S.W. Oak, Arnold Postlethwaite, Zongtao Lin, **Wei Li**, Yukimasa Takeda, Anton M. Jetten, Robert C. Tuckey, “Characterization of a new pathway that activates lumisterol in vivo to biologically active hydroxylumisterols”, *Sci. Rep.*, 2017, in press.
127. Hao Chen, Kinsie Arnst, Zongtao Lin, **Wei Li***, “Recent advances in tubulin inhibitor-based antibody-drug conjugating strategies for cancer therapy”, *Molecules*, 2017, 22, 1281-1309.
126. Andrzej T. Slominski, Anna A Brozyna, Cezary Skobowiat, Michal A. Zmijewski, Tae-Kang Kim, Zorica Janjetovic, Allen S. Oak, Wojciech Jozwicki, Anton M. Jetten, Rebecca S. Mason, Craig Elmets, **Wei Li**, Robert M. Hoffman, . Robert C. Tuckey, “On The Role Of Classical And Novel Forms Of Vitamin D In Melanomaprogression And Management”, *Journal of Steroid Biochemistry and Molecular Biology*, accepted on 6/23/2017. PMID: 28676457 DOI: 10.1016/j.jsbmb.2017.06.013
125. Shanshan Deng, Zongtao Lin, and **Wei Li***, “Recent advances in antibody-drug conjugates for breast cancer treatment”, *Curr. Med. Chem.*, accepted, **2017**. PMID: 28554322 DOI: 10.2174/0929867324666170530092350.
124. Min Xiao, Yi Xue, Zhongzhi Wu, Zi-Ning Lei, Jin Wang, Zhe-Sheng Chen, and **Wei Li***, “Design, Synthesis and Biological Evaluation of Selective Survivin Inhibitors”, *J. Biomed. Res.*, in press, **2017**.
123. Shivaputra A Patil, James K Addo, Hemantkumar Deokar, Shan Sun, Jin Wang, **Wei Li**, D Parker Suttle, Wei Wang, Ruiwen Zhang, and John K Buolamwini, “Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b]indole Derivatives as Broad-Spectrum Potent Anticancer Agents”, *Drug Designing: Open Access*, accepted as 2/27/2017, in press.
122. Ruinan Yang, Goutam Mondal, Rachel A. Ness, Kinsie Arnst, Vaibhav Mundra, Duane D. Miller, **Wei Li**, Ram I. Mahato*, “Polymer Conjugate of a Microtubule Destabilizer Inhibits Lung Metastatic Melanoma”, *J. Controlled Release*, 2017, 249:32-41. PMID: 28130039 PMCID: PMC5502538.
121. Andrzej T. Slominski, Tae-Kang Kim, Judith V. Hobrath, Allen S.W. Oak, Edith K.Y. Tang, Elaine W. Tieu, **Wei Li**, Robert C. Tuckey, Anton M. Jetten, "Endogenously produced nonclassical vitamin D hydroxy-metabolites act as biased agonists on VDR and inverse agonists on ROR α and ROR γ ", *Journal of Steroid Biochemistry and Molecular Biology*, in press, <http://www.sciencedirect.com/science/article/pii/S0960076016302606>.
120. Wang B, Liu Y, Huang L, Chen J, Li JJ, Wang R, Kim E, Chen Y, Justicia C, Sakata K, Chen H, Planas A, Ostrom RS, **Li W**, Yang G, McDonald MP, Chen R, Heck DH, Liao FF. A CNS-permeable Hsp90 inhibitor rescues synaptic dysfunction and memory loss in APP-overexpressing Alzheimer's mouse model via an HSF1-mediated mechanism. *Mol Psychiatry*, 22:990-1001, (**2017**). PMID: 27457810 PMCID: PMC5323357

(2016)

119. Souvik Banerjee, Dong-Jin Hwang, **Wei Li*** and Duane D. Miller*, “Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis”, *Molecules*, 21(11). pii: E1468, **2016**. PMID: 27827858.
118. Liu M, Dong J, Lin Z, Niu Y, Zhang X, Jiang H, Guo N, **Li W**, Wang H, Chen S. Rapid screening of transferrin-binders in the flowers of *Bauhinia blakeana* Dunn by on-line high-performance liquid chromatography-diode-array detector-electrospray ionization-ion-trap-time-of-flight-mass spectrometry-transferrin-fluorescence detection system. *J Chromatogr A*. **2016**;1450:17-28. PubMed PMID: 27178150.

117. Lin Z, Marepally SR, Ma D, Kim TK, Oak AS, Myers LK, Tuckey RC, Slominski AT, Miller DD, **Li W.*** Synthesis and Biological Evaluation of Vitamin D3 Metabolite 20S,23S-Dihydroxyvitamin D3 and Its 23R Epimer. *J Med Chem.* **2016**;59(10):5102-8. PubMed PMID: 27070779.
116. Lin Z, Marepally SR, Kim TK, Janjetovic Z, Oak AS, Postlethwaite AE, Myers LK, Tuckey RC, Slominski AT, Miller DD, **Li W.*** Design, Synthesis and Biological Activities of Novel Gemini 20S-Hydroxyvitamin D3 Analogs. *Anticancer Res.* **2016**;36(3):877-86. PubMed PMID: 26976974.
115. Yi B, Chang H, Ma R, Feng X, **Li W**, Piazza GA, Xi Y. Inhibition of breast cancer cell motility with a non-cyclooxygenase inhibitory derivative of sulindac by suppressing TGFbeta/miR-21 signaling. *Oncotarget.* **2016**;7(7):7979-92. PubMed PMID: 26769851; PubMed Central PMCID: PMC4884969.
114. Wu X, Wang Q, **Li W.*** Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site. *Anticancer Agents Med Chem.* **2016**;16(10):1325-38. PubMed PMID: 26899186.
113. Ajeeth K. Pingili, Mehmet Kara, Nayaab Khan, Anne M. Estes, Zongtao Lin, **Wei Li**, Frank J. Gonzalez and Kafait U. Malik. "6 β -Hydroxytestosterone, a Cytochrome P450 1B1 Metabolite of Testosterone Contributes to Angiotensin II-Induced Hypertension and its Pathogenesis in Male Mice", *Hypertension*, 67(5):916-26, **(2016)**. PMID: 26928804 PMCID: PMC4833582.

(2015)

112. Andrzej T. Slominski, Tae-Kang Kim, **Wei Li**, and Robert C. Tuckey, "Classical and non-classical metabolic transformation of vitamin D in dermal fibroblasts", *Exp. Dermatol.*, accepted as 9/30/2015, **2015**.
111. Qinghui Wang, Zongtao Lin, Tae-Kang Kim, Andrzej T. Slominski, Duane D. Miller, and **Wei Li***, "Total synthesis of biologically active 20S-hydroxyvitamin D3", *Steroids*, 104:153-62, **2015**. PMID: 26433048 PMCID: PMC4659745.
110. Zongtao Lin[#], Srinivasa Reddy Marepally[#], Dejian Ma, Linda K. Myers, Arnie E. Postlethwaite, Robert C. Tuckey, Tae-Kang Kim, Junming Yue, Andrzej T. Slominski, Duane D. Miller, **Wei Li***, ([#]equal first authors) "Chemical synthesis and biological activities of 20S,24S/R-dihydroxyvitamin D3 epimers and their 1 α -hydroxyl derivatives", *J. Med. Chem.*, 58(19):7881-7887, **2015**. PMID: 26367019 PMCID: PMC4613797
109. Souvik Banerjee, Jin Wang, Susan Pfeffer, Dejian Ma, Lawrence Pfeffer, Shivaputra Patil, **Wei Li**, Duane Miller, "Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel 5H-Chromenopyridines as Potential Anti-Cancer Agents", *Molecules*, 20:17152-17165, **2015**.
108. Andrzej T. Slominski, Tae-Kang Kim, **Wei Li**, Arnold Postlethwaite, Elaine Tieu, Edith Tang, Robert C. Tuckey, "Detection of novel CYP11A1-derived secosteroids in the human epidermis and serum and pig adrenal gland", *Scientific Reports*, accepted as 9/10/2015.
107. Dong-Jin Hwang[#], Jin Wang[#], **Wei Li***, Duane D. Miller*, "Structural Optimization of Indole Derivatives Acting at Colchicine Binding Site: Design, Synthesis, and Biological Evaluation of Potential Anticancer Agents", ([#]: Hwang and Wang are equal first authors), *ACS Med Chem Lett*, 6(9): 993-997, PMID 26396686, **(2015)**.
106. Zongtao Lin and **Wei Li***, "Vitamin D and Its Analogs in Inflammatory Diseases", *Curr. Top. Med. Chem.*, invited review, accepted as 6/20/2015.
105. Vaibhav Mundra, **Wei Li**, and Ram I. Mahato, "Overcoming the Resistance Barrier for Effective Treatment of Melanoma", *Nanomedicine*, accepted on 6/11/2015, **(2015)**.
104. Rachel Ann Ness, Duane D Miller, and **Wei Li***, "The role of vitamin D in cancer prevention", *Chinese Journal of Natural Medicines*, invited review, accepted as 5/29/2015. **(2015)**.
103. Min Xiao, Jin Wang, Zongtao Lin, Yan Lu, Zhenmei Li, Stephen W. White, Duane D. Miller, and **Wei Li***, "Design, Synthesis and SAR Studies of Novel Survivin Inhibitors with Potent Antiproliferative Properties", *PLoS One*, 10(6): e0129807. **(2015)**. PMID: 26070194; PMCID: PMC4466525.
102. Georgina N. Masoud, Jin Wang, Jianjun Chen, Duane Miller, and **Wei Li***, "Design, Synthesis and Biological Evaluation of Novel HIF-1 α Inhibitors", *Anticancer Research*, accepted as 4/15/2015 **(2015)**.

101. Georgina N. Masoud and **Wei Li***, "HIF-1 α Pathway: Role, Regulation and Intervention for Cancer Therapy", **Acta Pharmaceutica Sinica B**, 5(5): 378-389, invited review, <http://dx.doi.org/10.1016/j.apsb.2015.05.007>, (2015). Selected as the "2017 Outstanding Paper Award" in Acta Pharmaceutica Sinica B.
100. Vaibhav Mundra, Yang Peng, **Wei Li**, Duane D. Miller and Ram I. Mahato, "Systemic Delivery of Nanoparticle Formulation of Novel Tubulin Inhibitor for Treating Metastatic Melanoma", under revision, **Drug Delivery and Translational Research**, accepted as 3/30/2015, (2015)
99. Elaine W. Tieu, **Wei Li**, Jianjun Chen, Tae-Kang Kim, Dejian Ma, Andrzej T. Slominski and Robert C. Tuckey, "Metabolism of 20-Hydroxyvitamin D3 and 20,23-Dihydroxyvitamin D3 by Rat and Human CYP24A1", accepted as 2/17/2015, **Journal of Steroid Biochemistry and Molecular Biology**.
98. Tae-Kang Kim, Zongtao Lin, **Wei Li**, Russel J. Reiter, and Andrzej T. Slominski, "N1-acetyl-5-methoxykynuramine (AMK) is produced in the human epidermis and shows anti-proliferative effects", **Endocrinology**, accepted as 2/11/2015.
97. Andrzej T. Slominski, Zorica Janjetovic, Tae-Kang Kim, Piotr Wasilewski, Sofia Rosas, Sherie Hanna, **Wei Li**, Robert, C Tuckey, "Novel Non-Calcemic Secosteroids That Are Produced By Human Epidermal Keratinocytes Protect Against Solar Radiation", **Journal of Steroid Biochemistry and Molecular Biology**, accepted as 1/20/2015. PMID: 25617667.
96. Min Xiao and **Wei Li***, "Recent Advances on Small Molecule Survivin Inhibitors", **Curr Med Chem**, accepted as 1/9/2015, (2015). PMID: 25613234.
95. Tae-Kang Kim, Zongtao Lin, William J. Tidwell, **We Li**, and Andrzej T. Slominski, "Melatonin and its metabolites accumulate in the human epidermis in vivo and inhibit proliferation and tyrosinase activity in epidermal melanocytes in vitro", **Molecular and Cellular Endocrinology**, 404:1–8, (2015).
94. Andrzej T. Slominski, **Wei Li**, Tae-Kang Kim, Igor Semak, Jin Wang, Jordan K. Zjawiony, Robert C. Tuckey, "Novel activities of CYP11A1 and their potential physiological significance", **Journal of Steroid Biochemistry and Molecular Biology**, 151:25-37, (2015). PMID: 25448732 PMCID: PMC4757911

(2014)

93. Robert C. Tuckey, Andrzej T. Slominski, Chloe Y. S. Cheng, Jianjun Chen, Tae-Kang Kim, Min Xiao and Wei Li, "Lumisterol is metabolized by CYP11A1: discovery of a new pathway", **International Journal of Biochemistry & Cell Biology**, 55:24-34, (2014). PMID: 25130438, PMCID: PMC4252613
92. Yan Lu, Jianjun Chen, Jin Wang, Chien-Ming Li, Sunjoo Ahn, Christina M. Barrett, James T. Dalton, **Wei Li***, and Duane D. Miller*, "Design, Synthesis, and Biological Evaluation of Stable Colchicine Binding Site Tubulin Inhibitors as Potential Anticancer Agents", **J. Med. Chem.**, 57(17):7355-66, (2014). PMID: 25122533, PMCID: PMC4161160.
91. Jianjun Chen, Jin Wang, Luciana P. Schwab, Kyung-Tae Park, Tiffany N Seagroves, Lisa K. Jennings, Duane D. Miller, **Wei Li***, "Novel Benzimidazole Analogs as Potent HIF-1 α Inhibitors: Biological Evaluation, Profiling Drug-like Properties, and Biotransformation", **Anticancer Research**, 34(8):3891-3904, (2014). PMID: 25075010.
90. Jianjun Chen, Jin Wang, Tae-Kang Kim, Elaine W Tieu, Edith K. Y. Tang, Zongtao Lin, Dianne Kovacic, Duane D. Miller, Arnold Postlethwaite, Robert C. Tuckey, Andrzej T. Slominski, and **Wei Li***, "Novel vitamin D analogs as potential therapeutics: metabolism, toxicity profiling, and antiproliferative activity", **Anticancer Research**, 34(5):2153-2163, (2014). PMID: 24778017, PMCID: PMC4015637
89. Andrzej T. Slominski, Tae-Kang Kim, Yukimasa Takeda, Zorica Janjetovic, Anna A. Brozyna, Cezary Skobowiat, Jin Wang, Arnold Postlethwaite, **Wei Li**, Robert C. Tuckey, Anton M. Jetten, "ROR α and ROR γ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxy-vitamin D", **FASEB J.** 28(7), 2775-2789, (2014). PMID: 24668754, PMCID: PMC4062828.
88. **Wei Li*** and Bob M Moore*, "The Effect of Arvanil on Prostate Cancer Cells Studied by Whole Cell High Resolution Magic Angle Spinning NMR", **Modern Chemistry & Applications**, 2(1):119, (2014).
87. Jin Wang and **Wei Li***, "Discovery of Novel SMAC Mimetics as Selective IAP Inhibitors", **J. Pharm Exp Ther**, 349(2):319-29, (2014). PMID: 24623800, PMCID: PMC3989805.

86. Zongtao Lin, Ruinan Yang, Zheng Guan, Ailiang Chen, and **Wei Li***, "UPLC Separation and QToF-MS Identification of Major Alkaloids in Plumula Nelumbinis", **Phytochemical Analysis**, 25(6):485-494, (2014). PMID: 24733684.
85. Andrzej T. Slominski, Tae-Kang Kim, Haleem Z. Shehabi, Edith Tang, Heather A. E. Benson, Igor Semak, Zongtao Lin, Charles R. Yates, Jin Wang, **Wei Li**, and Robert C. Tuckey, "In vivo production of novel vitamin D2 hydroxy-derivatives by human placentas, epidermal keratinocytes, Caco-2 colon cells and the adrenal gland", **Molecular and Cellular Endocrinology**, 383: 181-192, (2014). PMID: 24382416, PMCID: PMC3997123.
84. Jin Wang, Jianjun Chen, Duane D. Miller and **Wei Li***, "Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcome Vemurafenib Acquired Resistance in BRAFV600E Melanoma", **Molecular Cancer Therapeutics**, 13(1): 16-26, (2014). PMID: 24249714. PMCID: PMC3947172. This article is featured in Highlights of this issue.
83. Andrzej T. Slominski, Michal A. Zmijewski, Igor Semak, Blazej Zbytek, Alexander Pisarchik, **Wei Li**, Jordan Zjawiony, and Robert C. Tuckey, "Cytochromes P450 and Skin Cancer: Role of Local Endocrine Pathways", **Anti-Cancer Agents in Medicinal Chemistry**, 14(1):77-96, (2014), PMID: 23869782, PMCID: PMC3740756.
82. Andrzej T. Slominski, Tae-Kang Kim, **Wei Li**, Ae-Kyung Yi, Arnold Postlethwaite, and Robert C. Tuckey, "The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions", **Journal of Steroid Biochemistry and Molecular Biology**, 144:28-39, (2014), PMID: 24176765, PMCID: PMC4002668.

(2013)

81. Andrzej Slominski, Zorica Janjetovic, Robert C. Tuckey, Minh N. Nguyen, Keka G. Bhattacharya, Jin Wang, **Wei Li**, Yan Jiao, Weikuan Gu, Monica Brown, and Arnold E. Postlethwaite, "20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo", **Journal of Clinical Endocrinology & Metabolism**, 98(2): E298-303, (2013).
80. Hovig Kouyoumdjian, David C. Zhu, Mohammad H. El-Dakdouki, Kelly Lorenz, Jianjun Chen, **Wei Li**, Xuefei Huang, "Glyconanoparticle Aided Detection of β -Amyloid by Magnetic Resonance Imaging and Attenuation of β -Amyloid Induced Cytotoxicity", **ACS Chemical Neuroscience**, 4(4):575-84, (2013). PMID: 23590250, PMCID: PMC3629742.
79. Andrzej Slominski, Bazej Zbytek, Georgios Nikolakis, Pulak R. Manna, Cezary Skobowiat, Michal Zmijewski, **Wei Li**, Zorica Janjetovic, Arnold Postlethwaite, Christos C. Zouboulis, Robert C. Tuckey, "Steroidogenesis in the skin: implications for local immune functions", **The Journal of Steroid Biochemistry and Molecular Biology**, 137:107-23, (2013). PMID: 23435015, PMCID: PMC3674137.
78. Andrzej T. Slominski, Tae-Kang Kim, Michal A. Zmijewski, Zorica Janjetovic, **Wei Li**, Jianjun Chen, Ekaterina I. Kusniatsova, Igor Semak, Arnold Postlethwaite, Duane D. Miller, Jordan K. Zjawiony and Robert C. Tuckey, "Novel vitamin D photoproducts and their precursors in the skin", **Dermato-Endocrinology**, 5(1):7-19, (2013). PMID: 24494038, PMCID: PMC3897599
77. Edith K. Y. Tang, Jianjun Chen, Zorica Janjetovic, Elaine W. Tieu, Andrzej T. Slominski, **Wei Li** and Robert C. Tuckey, "Hydroxylation of CYP11A1-derived products of vitamin D3 metabolism by human and mouse CYP27B1", **Drug Metabolism and Disposition**, 41(5):1112-24, (2013). PMID: 23454830, PMCID: PMC3629803.
76. Jianjun Chen, Andrzej T. Slominski, Duane D. Miller, and **Wei Li***, "Effects of sidechain length and composition on the kinetic conversion and product distribution of vitamin D3 analogs determined by real-time NMR", **Dermato-Endocrinology**, 5(1):142-149, (2013). PMID: 24494047, PMCID: PMC3897582
75. Tae-Kang Kim, Konrad Kleszczynski, Zorica Janjetovic, Trevor Sweatman, Zongtao Lin, **Wei Li**, Russel Reiter, Tobias Fischer, Andrzej T. Slominski, "Metabolism of melatonin and biological activity of intermediates of melatonergic pathway in human skin cells", **FASEB Journal**, 27(7):2742-55, (2013). PMID: 23620527, PMCID: PMC3688757.

74. Min Xiao, Sunjoo Ahn, Jin Wang, Jianjun Chen, Duane D. Miller, James T Dalton and **Wei Li*** "Discovery of 4-Aryl-2-benzoyl-imidazoles As Tubulin Polymerization Inhibitor with Potent Antiproliferative Properties", **J. Med. Chem.**, 56(8):3318-29, PMID: 23547728, PMCID: PMC3668676, (2013).

(2012)

73. Elaine W. Tieu, Edith K. Y. Tang, Jianjun Chen, **Wei Li**, Minh N. Nguyen, Zorica Janjetovic, Andrzej Slominski and Robert C. Tuckey, "Rat CYP24A1 acts on 20-hydroxyvitamin D3 producing hydroxylated products with increased biological activity", **Biochemical Pharmacology**, 84(12), 1696-1704 (2012).
72. Andrzej T. Slominski, Tae-Kang Kim, Jianjun Chen, Minh N. Nguyen, **Wei Li**, Charles R. Yates, Trevor Sweatman, Zorica Janjetovic, Robert C. Tuckey, "Cytochrome P450scc-dependent metabolism of 7-dehydrocholesterol in placenta and epidermal keratinocytes", **International Journal of Biochemistry & Cell Biology**, 44, 2003–2018, (2012).
71. Anna N. Bukiya, Shivaputra Patil, **Wei Li**, Duane Miller, and Alex M. Dopico, "Ca²⁺- and voltage-gated potassium (BK) channel activators in 5beta-cholanic acid-3alpha-ol analogue series with modifications in lateral chain", **ChemMedChem**, 7(10):1784-92, (2012). PMID: 22945504.
70. Vaibhav Mundra, Yan Lu, Michael Danquah, **Wei Li**, Duane D. Miller and Ram I. Mahato, "Formulation and Characterization of Polyester/Polycarbonate Nanoparticles for Delivery of a Novel Microtubule Destabilizing Agent", **Pharm Res**, 29(11):3064-74, (2012). PMID: 23054088, PMCID: PMC3646297.
69. Robert C. Tuckey, Minh N. Nguyen, Jianjun Chen, Andrzej T. Slominski, Donna M. Baldisseri, Elaine W. Tieu, Jordan K. Zjawiony, and **Wei Li**, "Human cytochrome P450scc (CYP11A1) catalyses epoxide formation with ergosterol", **Drug Metab Dispos**, 40(3):436-444, (2012).
68. Elaine W. Tieu, **Wei Li**, Jianjun Chen, Donna M. Baldisseri, Andrzej T. Slominski, Robert C. Tuckey, "Metabolism of cholesterol, vitamin D3 and 20-hydroxyvitamin D3 incorporated into phospholipid vesicles by human CYP27A1", **J Steroid Biochem Molec Biol.**, 129(3-5):163-71, (2012).
67. Jin Wang, Andrzej Slominski, Robert Tuckey, Zorica Janjetovic, Anand Kulkarni, Jianjun Chen, Arnold E. Postlethwaite, Duane Miller, **Wei Li***, "20-Hydroxylvitamin D3 possesses high efficacy against proliferation of cancer cells while being non-toxic", **Anticancer Research**, 32: 739-746, (2012).
66. Zhao Wang, Jianjun Chen, Jin Wang, Sunjoo Ahn, Chien-Ming Li, Yan Lu, Vivian S. Loveless, James T. Dalton, Duane D. Miller, **Wei Li***, "Novel Tubulin Polymerization Inhibitors Overcome Multidrug Resistance and Reduce Melanoma Lung Metastasis", **Pharmaceutical Research**, 29(11):3040-52, (2012). PMID: 22410804, PMCID: PMC3659804.
65. Mohammad H. El-Dakdouki; David C. Zhu; Kheireddine El-Boubbou; Medha Kamat; Jianjun Chen, **Wei Li**, Xuefei Huang, " Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells " , **Biomacromolecules**, 13(4):1144-51, (2012).
64. Yan Lu, Jianjun Chen, Zorica Janjetovic, Phillip Michaels, Edith K Y Tang, Jin Wang, Robert C. Tuckey, Andrzej T. Slominski, **Wei Li***, Duane D. Miller*, " Design, synthesis, and biological action of 20R-hydroxyvitamin D3", (*: both Li and Miller are corresponding authors), **J. Med. Chem.**, 55(7):3573-7, (2012). PMID: 22404326, PMCID: PMC3332540.
63. Tae-Kang Kim[#], Jin Wang[#], Zorica Janjetovic, Jianjun Chen, Robert C. Tuckey, Minh N. Nguyen, Edith K. Y. Tang, Duane Miller, **Wei Li***, and Andrzej T. Slominski*, "Correlation between secosteroid induced vitamin D receptor activity in melanoma cells and computer-modeled receptor binding strength" (#: equal first authors; *: both Li and Slominski are corresponding authors), **Molecular and Cellular Endocrinology**, 361(1-2):143-52, (2012). PMID: 22546549, PMCID: PMC3409337.
62. Shivaputra A. Patil*, Jin Wang, Xiaochen S. Li, Jianjun Chen, Terreia S. Jones, Amira H. Ahmed, Renukadevi Patil, William L. Seibel, **Wei Li***, and Duane D. Miller*, " New substituted 4H-chromenes as anticancer agents", (*:corresponding authors). **Bioorg. Med. Chem. Lett.**, 22(13):4458-61, (2012).
61. Andrzej T. Slominski, Tae-Kang Kim, Haleem Z. Shehabi, Igor Semak, Edith K.Y. Tang, Minh N. Nguyen, Heather A. E. Benson, Elena Korik, Zorica Janjetovic, Jianjun Chen, Charles R. Yates, Arnold Postlethwaite, **Wei Li**, and Robert C. Tuckey, "In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1", **FASEB J.**, 26(9):3901-15, (2012). PMID: 22683847, PMCID: PMC3425822.

60. Yan Lu, Jianjun Chen, Min Xiao, **Wei Li**, Duane D. Miller, "An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site", **Pharm. Res.**, 29(11):2943-71, (2012). PMID: 22814904, PMCID: PMC3667160.
59. Chien-Ming Li, Yan Lu, Jianjun Chen, Terrence A. Costello, Ramesh Narayanan, Mara N. Dalton, Linda M. Snyder, Sunjoo Ahn, **Wei Li**, Duane D. Miller, and James T. Dalton, "Orally Bioavailable Tubulin Antagonists for Paclitaxel-Refractory Cancer", **Pharm. Res.**, 29(11):3053-63, (2012). PMID: 22760659, PMCID: PMC3646298.
58. Jianjun Chen, Sunjoo Ahn, Jin Wang, Yan Lu, James T. Dalton, Duane D. Miller, and **Wei Li***, "Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents", **J. Med. Chem.**, 55(19):7285-9, (2012). PMID: 22783954, PMCID: PMC3426659.

(2011)

57. Renukadevi Patil, Shivaputra Patil, XiangDi Wang, Fei Ma, William E. Orr, **Wei Li**, Charles R. Yates, Eldon E. Geisert, Duane D. Miller, "Synthesis and evaluation of new 1,2,3,4-tetrahydroisoquinoline analogs as antiglioma agents", **Medicinal Chemistry Research**, 20, 131-137, (2011).
56. Chien-Ming Li[#], Zhao Wang[#], Yan Lu, **Wei Li***, Sunjoo Ahn, Ramesh Narayanan, Jeffrey D. Kearbey, Deanna N. Parke, Duane D. Miller, **James T. Dalton***, "Biological activity of 4-Substituted Methoxybenzoyl-Aryl-Thiazole (SMART): An active microtubule inhibitor", **Cancer Res**, 71(1), 216-224, (2011). ([#] Li and Zhao are equal first authors. * both Li and Dalton are corresponding authors).
55. Michal A. Zmijewski, **Wei Li**, Jordan K. Zjawiony, Jianjun Chen, Trevor W. Sweatman, Duane D. Miller and Andrzej T. Slominski, "Synthesis and photochemical transformation of 3 β ,21-dihydroxypregna-5,7-dien-20-one to novel secosteroids that show anti-melanoma activity Steroids", **Steroids**, 76, 193–203, (2011).
54. Andrzej T. Slominski, Tae-Kang Kim, Zorica Janjetovic, Robert C. Tuckey, Radoslaw Bieniek, Junming Yue, **Wei Li**, Jianjun Chen, Minh N. Nguyen, Edith K.Y. Tang, Duane Miller, Tai C. Chen, Michael Holick, "20-hydroxyvitamin D2 is a non-calcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells", **Am J Physiol. Cell Physiol.**, 300(3):C526-41, (2011).
53. Andrzej Slominski, **Wei Li**, Syamal K. Bhattacharya, Jianjun Chen, Robert C Tuckey, Duane Miller, Arnold E. Postlethwaite, " Vitamin D Analogs 17,20S(OH)(2)pD and 17,20R(OH)(2)pD Are Noncalcemic and Exhibit Antifibrotic Activity", **J Invest Dermatol.**, 131(5):1167-9, (2011).
52. Yan Lu, Chien-Ming Li, Zhao Wang, Jianjun Chen, Michael L. Mohler, **Wei Li**, James T. Dalton, Duane D. Miller, "Design, Synthesis and SAR Studies of Novel Colchicine Binding Site Tubulin Inhibitors as Potent and Orally Bioavailable Anticancer Agents", **J. Med. Chem.**, 54(13):4678-93, (2011).
51. Robert C. Tuckey, **Wei Li**, Haleem Shehabi, Zorica Janjetovic, Minh N. Nguyen, Tae-Kang Kim, Jianjun Chen, Danielle E. Howell, Heather Benson, Trevor Sweatman, Donna M. Baldisseri, and Andrzej Slominski, "Production of 22-hydroxy-metabolites of vitamin D3 by cytochrome P450scc (CYP11A1) and analysis of their biological activities on skin cells", **Drug Metab Dispos**, 39(9), 1577-1588, (2011).
50. Jianjun Chen, Chien-Ming Li, Jin Wang, Sunjoo Ahn, Zhao Wang, Yan Lu, James T. Dalton, Duane D. Miller, **Wei Li***, "Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization", **Bioorg. Med. Chem.**, 19(16):4782-95, (2011).
49. Chien-Ming Li, Jianjun Chen, Yan Lu, Ramesh Narayanan, Deanna N. Parke, **Wei Li**, Duane D. Miller, and James T. Dalton, "Pharmacokinetic Optimization of 4-Substituted Methoxybenzoyl-Aryl-Thiazole (SMART) and 2-Aryl-4-Benzoyl-Imidazole (ABI) for Improving Oral Bioavailability", **Drug Metab Dispos**, 39(10):1833-1839, (2011).

(2010)

48. Gupte R, Siddam A, Lu Y, **Li W**, Fujiwara Y, Panupinthu N, Pham TC, Baker DL, Parrill AL, Gotoh M, Murakami-Murofushi K, Kobayashi S, Mills GB, Tigyi G, Miller DD., "Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid", **Bioorg Med Chem Lett**. 20(24):7525-8, (2010).

47. Medha Kamat, Kheireddine El-Boubbou, David C. Zhu, Teri Lansdell, Xiaowei Lu, **Wei Li**, and Xuefei Huang, "Hyaluronic Acid Immobilized Magnetic Nanoparticles for Active Targeting and Imaging of Macrophages", **Bioconjugate Chemistry**, 21 (11), 2128–2135, (2010).
46. Jianjun Chen, Zhao Wang, Chien-Ming Li, Yan Lu, James T. Dalton, Duane D. Miller, **Wei Li**, "Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting tubulin polymerization as potential agents for resistant cancer treatment", **J Med Chem**, 53 (20), pp 7414–7427, (2010).
45. Dergunov, Sergey; Kesterson, Katrina; **Li, Wei**; Wang, Zhao; Pinkhassik, Eugene. "Synthesis, Characterization, and Long-Term Stability of Hollow Polymer Nanocapsules with Nanometer-Thin Walls", **Macromolecules**, 43(18), 7785-92, (2010).
44. Edith K. Y. Tang, **Wei Li**, Zorica Janjetovic, Minh N. Nguyen, Zhao Wang, Andrzej Slominski, and Robert C. Tuckey, "Purified Mouse CYP27B1 Can Hydroxylate 20,23-Dihydroxyvitamin D3, Producing 1 α ,20,23-Trihydroxyvitamin D3, Which Has Altered Biological Activity", **Drug Metabolism and Disposition**, 38, 1553-1559, (2010).
43. **Wei Li**, Jianjun Chen, Zorica Janjetovic, Tae-Kang Kim, Trevor Sweatman, Yan Lu, Jordan Zjawiony, Robert C Tuckey, Duane Miller, Andrzej Slominski, "Chemical Synthesis of 20S-hydroxyvitamin D3, which shows anti-proliferative activity", **Steroids**, 75, 926–935, (2010).
42. Yan Lu, Zhao Wang, Chien-Ming Li, Jianjun Chen, James T. Dalton, Wei Li, Duane D. Miller, "Synthesis, in vitro structure–activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents, **Bioorg. Med. Chem.**, 18(2):477-95 (2010).
41. Andrzej T. Slominski, Zorica Janjetovic, Brian E. Fuller, Michal A. Zmijewski, Robert C. Tuckey, Minh N. Nguyen, Trevor Sweatman, **Wei Li**, Jordan Zjawiony, Duane Miller, Tai C. Chen, Gerard Lozanski, Michael F. Holick, "Novel products of vitamin D3 or pro-vitamin D3 (7-dehydrocholesterol) metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity", **PLOS One**, 5(3):e9907 (2010).
40. Tae-Kang Kim[#], Jianjun Chen[#], **Wei Li**, Jordan Zjawiony, Duane Miller, Zorica Janjetovic, Robert C Tuckey, and Andrzej Slominski, "A New Steroidal 5,7-Diene Derivative, 3 β -Hydroxyandrosta-5, 7-Diene-17 β -Carboxylic Acid, Shows Potent Anti-proliferative Activity", **Steroids**, 75(3):230-9 (2010). ([#]: equal first authors)
39. Feng Li, Yan Lu, **Wei Li**, Duane D. Miller and Ram I. Mahato, "Synthesis, Formulation and in vitro Evaluation of a Novel Microtubule Stabilizer, SMART-100", **J. Controlled Release**, 143(1):151-8 (2010).
38. El-Boubbou, Kheireddine; Zhu, David; Vasileiou, Chrysoula; Borhan, Babak; Prosperi, Davide; **Li, Wei**; Huang, Xuefei, "Magnetic Glyco-Nanoparticles: A Tool to Detect, Differentiate and Characterize Carbohydrate-binding Profiles of Cancer Cells via Magnetic Resonance Imaging", **J. Am. Chem. Soc.**, 132, 4490–4499 (2010).

(2009)

37. Jianjun Chen, Jiang-wei Zhang, Ling Yang and **Wei Li***, "Structure elucidation of major metabolites from medroxyprogesterone acetate by P450", **Chem. Pharm. Bull.**, 57(8),835-839, (2009).
36. Zhao Wang, Yan Lu, William Seibel, Duane D. Miller, and **Wei Li***, " Identifying Novel Molecular Structures for Advanced Melanoma by Ligand-Based Virtual Screening", **J. Chem. Info. Model.**, 49(6):1420-7, (2009).
35. Yan Lu, Chien-Ming Li, Zhao Wang, Charles R. Ross, II, Jianjun Chen, James Dalton, **Wei Li**, Duane. D. Miller, "Discovery of 4-Substituted Methoxybenzoyl-Aryl-Thiazole as Novel Anticancer Agents: Synthesis, Biological Evaluation and Structure-Activity Relationships", **J. Med. Chem.**, 52(6):1701-1711, (2009).
34. **Wei Li***, Radomir Slominski, Andrzej T. Slominski, "HRMAS NMR Analysis of Metabolic Changes in Melanoma Cells After induction of Melanogenesis", **Anal. Biochem.**, 386(2):282-4, (2009).
33. Minh N Nguyen, Andrzej Slominski, **Wei Li**, Yun R Ng, and Robert C Tuckey, "Metabolism of vitamin D2 to 17,20,24-trihydroxyvitamin D2 by cytochrome P450scc (CYP11A1)", **Drug Metabolism and Disposition**, 37: 761-767, (2009).
32. A.T. Slominski, M.A. Zmijewski, I. Semak, T. Sweatman, Z. Janjetovic, **W. Li**, J. Zjawiony, R.C. Tuckey, "Sequential metabolism of 7-dehydrocholesterol to steroidal 5,7-dienes in adrenal glands and its biological implication in the skin", **PLOS One**, 4(2):e4309, (2009).

31. Michal A. Zmijewski, **Wei Li**, Jordan K. Zjawiony, Trevor W. Sweatman, Jianjun Chen, Duane D. Miller and Andrzej T. Slominski, "Synthesis and photo-conversion of two enantiomers (20R or S) of 3 β , 17 α , 20-trihydroxypregna-5,7-diene", **Steroids**, 74(2):218-28, (2009).
30. Hong-Bin Fang, Guo-Liang Tian, **Wei Li** and Ming Tan, "Design and Sample Size for Evaluating Combinations of Drugs of Linear and Loglinear Dose Response Curves", **Journal of Biopharmaceutical Statistics**, 19:625-640, (2009).
29. **Wei Li**, Dong Jin Hwang, Dieter Cremer, Henry Joo, Elfi Kraka, Juhyun Kim, Charles R. Ross II, Viet Q. Nguyen, James T. Dalton, and Duane D. Miller, "Absolute configuration determination of epimeric sulfoxide-linked bicalutamide derivatives", **Chirality**, 21(6):578-83 (2009).

(2008)

28. Robert C. Tuckey, Zorica Janjetovic, **Wei Li**, Minh N. Nguyen, Michal A. Zmijewski, Jordan Zjawiony and Andrzej Slominski, "Metabolism of 1 α -hydroxyvitamin D3 by cytochrome P450scc", **J Steroid Biochem Molec Biol.**, (2008), 112, 213-219.
27. Hongyu Zhou, Fenfang Du, Xi Li, Bin Zhang, **Wei Li**, Bing Yan, "Characterization of Organic Molecules Attached to Gold Nanoparticle Surface Using High Resolution Magic Angle Spinning NMR", **J. Phys. Chem.** (2008), 112 (49), 19360–19366.
26. Michal A. Zmijewski, **Wei Li**, Jordan K. Zjawiony, Trevor W. Sweatman, Jianjun Chen, Duane D. Miller and Andrzej T. Slominski, "Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives", **Photochem. Photobiol. Sci.**, (2008), 7(12), 1570-1576
25. Jianjun Chen, Zhao Wang, Yan Lu, James T. Dalton, Duane D. Miller, and **Wei Li**, "Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma", **Bioorg. Med. Chem. Lett.**, 18, 3183-3187, (2008).
24. Shivaputra Patil, Anna N. Bukiya, **Wei Li**, Alejandro M. Dopico, and Duane Miller, "Design and synthesis of hydroxy-alkynoic acids and their methyl esters as novel activators of BK channels", **Bioorg. Med. Chem. Lett.**, 18, 3427-3430, (2008).
23. Robert C. Tuckey, **Wei Li**, Jordan K. Zjawiony, Michal A. Zmijewski, Minh N. Nguyen, Trevor Sweatman, Duane Miller and Andrzej Slominski, "Pathways and Products for the Metabolism of Vitamin D3 by Cytochrome P450scc", **FEBS J.** (2008), 275(10), 2585-2596.

(2007)

22. **Wei Li**, Yan Lu, Zhao Wang, James T. Dalton, and Duane D. Miller, "Synthesis and antiproliferative activity of thiazolidine analogs for melanoma", **Bioorg. Med. Chem. Lett.**, 17(15), 4113-4117, (2007).
21. **Wei Li***, Zhao Wang, Veeresa Gududuru, Blazej Zbytek, Andrzej T. Slominski, James T. Dalton, and Duane D. Miller, "Structure-Activity Relationship Studies of Arylthiazolidine Amides as Selective Cytotoxic Agents for Melanoma", **Anticancer Research**, 27, 883-888, (2007).

(2006)

20. Michael L. Mohler, Gyong-Suk Kang, Seoung-Soo Hong, Renukadevi Patil, Oleg V. Kirichenko, **Wei Li**, Igor M. Rakov, Eldon E. Geisert, and Duane D. Miller, "Discovery of Antiglioma Activity of Biaryl 1,2,3,4-Tetrahydroisoquinoline Derivatives and Conformationally Flexible Analogs", **J. Med. Chem.**, 49(19), 5845-5848, (2006)
19. **Wei Li***, "Multidimensional HRMAS NMR: a platform for in vivo studies using intact bacteria cells", invited review, **The Analyst**, 131, 777-781, (2006)
18. Andrzej Slominski, Igor Semak, Jacobo Wortsman, Jordan Zjawiony, **Wei Li** and Robert C. Tuckey, "Alternative metabolism of vitamin D2 via P450scc system to 20-hydroxyvitamin D2 and 17,20-dihydroxyvitamin D2", **FEBS Journal**, 273, 2891-2901, (2006)
17. Renukadevi Patil, **Wei Li**, Charles R. Ross II, Elfi Kraka, Dieter Cremer, Michael L. Mohler, James T. Dalton, Duane D. Miller, "Cesium fluoride and tetra-n-butylammonium fluoride mediated 1,4-N \rightarrow O shift of disubstituted phenyl ring of a bicalutamide derivative", **Tetrahedron Letters**, 47(13). 3941-3944, (2006)

(2005)

16. **Wei Li***, Robin E. B. Lee, Richard E. Lee and Jinghu Li, "Methods for Acquisition and Assignment of Multi-Dimensional High-Resolution Magic Angle Spinning NMR of Whole Cell Mycobacteria", **Anal. Chem.**, 77, 5785-5792, (2005).
15. Andrzej Slominski, Igor Semak, Jordan Zjawiony, Jacobo Wortsman, **Wei Li**, Andre Szczesniowski, Robert C. Tuckey, "The cytochrome P450_{scc} system opens an alternate pathway of vitamin D₃ metabolism.", **FEBS Journal**, 272, 4080-4090, (2005).
14. Andrzej Slominski, Igor Semak, Jordan Zjawiony, Jacobo Wortsman, Michael N. Gandy, Jinghu Li, Blazej Zbytek, **Wei Li** and Robert C. Tuckey, "Enzymatic metabolism of ergosterol by cytochrome P450_{scc} (CYP11A1) to biologically active 17 α ,24-dihydroxyergosterol", **Chemistry & Biology**, 12(8), 931-939 (2005).
13. Robin E. B. Lee, **Wei Li**, Delphi Chatterjee and Richard E. Lee, "Structural Characterization of the Intact Mycobacterial Cell Wall Using 2D and 3D High-Resolution Magic-Angle Spinning NMR Spectroscopy", **Glycobiology**, 15 (2), 139-151 (2005).

Before Tenure-Track at UTHSC (1998-2004)

12. Mathangi Krishnamurthy, **Wei Li** and Bob M. Moore II, "Synthesis, Biological Evaluation, and Structural Studies on N1 and C5 Substituted Cycloalkyl Analogs of Pyrazole Class of CB1 and CB2 Ligands", **Bioorg. & Med. Chem.**, 12, 393-404 (2004).
11. Shilpa G. Lalchandani, Xiaoyang Zhang, Seoung Soo Hong, Stephen B. Liggett, **Wei Li**, Bob M. Moore II, Duane D. Miller and Dennis R. Feller, "Medetomidine Analogs As Selective Agonists For the Human α_2 -Adrenoceptors", **Biochem. Pharmacol.**, 67(1), 87-96 (2004).
10. Asha K. Nadipuram, Mathangi Krishnamurthy, Antonio M. Ferreira, **Wei Li** and Bob M. Moore, II, "Synthesis and Testing of Novel Classical Cannabinoids: Exploring the Side Chain Ligand Binding Pocket of the CB1 and CB2 Receptors", **Bioorg. & Med. Chem.**, 11, 3121-3132 (2003).
9. Nicholas J. Turro, Xue-gong Lei, Steffen Jockusch, **Wei Li**, Zhiqiang Liu, Lloyd Abrams and M. Francesca Ottaviani, "EPR Investigation of Persistent Radicals Produced from the Photolysis of Dibenzyl Ketones Adsorbed on ZSM-5 Zeolites", **J. Org. Chem.**, 67(8), 2606-2618 (2002)
8. Yali He, Donghua Yin, Minoli Perera, Leonid Kirkovsky, Nina Stourman, **Wei Li**, James T. Dalton, and Duane D. Miller, "Novel Nonsteroidal Ligands with High Binding Affinity and Potent functional Activity for the Androgen Receptor", **Europ. J. Med. Chem.**, 37, 619-634 (2002).
7. Nicholas J. Turro, Xue-Gong Lei, **Wei Li**, Zhiqiang Liu, and M. Francesca Ottaviani, "Adsorption of Cyclic Ketones on the External and Internal Surfaces of a Faujasite Zeolite (CaX). A Solid-State ²H NMR, ¹³C NMR, FT-IR, and EPR Investigation", **J. Am. Chem. Soc.**, 122, 12571-12581 (2000).
6. Nicholas J. Turro, Xue-Gong Lei, **Wei Li**, Zhiqiang Liu, Ann McDermott, M. Francesca Ottaviani, and Lloyd Abrams, "Photochemical and Magnetic Resonance Investigations of the Supramolecular Structure and Dynamics of Molecules and Reactive Radicals on the External and Internal Surface of MFI Zeolites", **J. Am. Chem. Soc.**, 122, 11649-11659 (2000).
5. Takashi Hirano, **Wei Li**, Lloyd Abrams, Paul J. Krusic, M. Francesca Ottaviani and N. J. Turro, "Supramolecular Steric Effects as the Means of Making Reactive Carbon Radicals Persistent. Quantitative Characterization of the External Surface of MFI Zeolites through a Persistent Radical Probe and a Langmuir Adsorption Isotherm", **J. Org. Chem.**, 65, 1319-1330 (2000).
4. **Wei Li**, Xuegong Lei, George Lem, Ann McDermott, Nicholas J. Turro, Nils Bottke and Waldemar Adam, "Oxygen and structural effect on silicalite ²⁹Si spin-lattice relaxation studied by high resolution ²⁹Si solid state NMR", **Chem. Mater.**, 12, 731-737 (2000).
3. Takashi Hirano, **Wei Li**, Lloyd Abrams, Paul J. Krusic, M. Francesca Ottaviani and N. J. Turro, "Reversible Oxygenation of a Diphenylmethyl Radical Rendered Supramolecularly Persistent" **J. Am. Chem. Soc.**, 121, 7170-7171 (1999).
2. Nicholas J. Turro, Ann McDermott, Xuegong Lei, **Wei Li**, Lloyd Abrams, M. Francesca Ottaviani, Hege Stogard Beard, Kendall N. Houk, Brett R. Beno and Patrick S. Lee, "Photochemistry of ketones adsorbed on size/shape selective zeolites. A supermolecular approach to persistent carbon centered radicals", **Chem. Commun.**, 697-698 (1998).

1. Nicholas J. Turro, Xuegong Lei, **Wei Li**, Ann McDermott, Lloyd Abrams, M. Francesca Ottaviani and Hege Stogard Beard, " Photochemistry and magnetic resonance spectroscopy as probes of supramolecular structures and migration pathways of organic molecules and radicals adsorbed on zeolites", **Chem. Commun.**, 695-696 (1998).